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Cervical screening in Australia 1998–1999 is the third annual report
based on key program activity, performance and outcome indicators
to monitor the achievements of the National Cervical Screening
Program. The report provides a comprehensive national picture 
of cervical screening in Australia for 1998–1999.
The report presents most recent information on participation in
cervical screening, rate of early re-screening, low-grade and 
high-grade abnormalities detected, incidence of cervical cancer 
and mortality. Analysis of incidence and mortality data by location
(rural, remote and metropolitan) as well as mortality by Indigenous
status are also presented. Where possible, data are presented by
State and Territory stratification.
This report will be relevant to anyone with an interest in women’s
health or cervical screening, including health planners and
administrators, various health practitioners, academic researchers
and the general public.
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Summary
• Between the two periods 1997-1998 and 1998-1999 cervical screening participation rates of
the target population (women aged 20 to 69 years) increased from 63.9% to 64.8%.
• There was a small increase in the participation rate in most 5-year age groups within the target
age group between the two periods 1997-1998 and 1998-1999. The largest increase - of 4.6% -
was in the age group 60-64 years.
• Overall, 2,777,324 women were screened for cervical abnormalities in the 1998-1999 period.
This is an increase of 55,674 women screened compared with the 2,721,650 women screened
during 1997-1998 period.
• Compliance with the recommended screening interval (two years following a negative smear)
is crucial in maintaining the effectiveness and the cost efficiency of the Program. Of a cohort
of women screened in February 1998 who had a negative Pap smear result, 43.1% were
rescreened in two years or less. This is in contrast to 46.7% women who were rescreened in
two years or less following a negative Pap smear in 1997.
• Of the 1998 cohort of women who had a negative Pap smear result, 35% had one additional
smear, 7% had two additional smears, and less than 2% had three or more additional smears in
the two years following their initial Pap smear.
• A low-grade abnormality includes atypia, warty atypia, possible CIN, equivocal CIN, and
CIN 1, while a high-grade abnormality is defined to include CIN 1/2, CIN 2 and CIN 3 or
adenocarcinoma in situ. The ratio of histologically confirmed low-grade abnormalities to high-
grade abnormalities was 1.4 for Australia in 1999, the same as for 1998. The 1998 ratio does
not include data for the Australian Capital Territory.
• In 1999, the National Cervical Screening Program detected 11,642 women with high-grade
abnormalities compared with 10,704 women with high-grade abnormalities detected in 1998.
This number was much higher in the younger age groups: in the 20-29 age group the rate of
high-grade abnormalities was over 17 per 1,000 women screened whereas it was less than
2 per 1,000 in women aged 55 years and over.
• The number of new cases of cervical cancer declined in Australia in recent years. There were
868 new cases in Australia in 1998 compared with 1,086 new cases detected in 1987. Cervical
cancer is one of the few cancers where screening can detect pre-cancerous lesions. Treatment
can prevent a large proportion of these pre-cancerous lesions progressing to cancer.
• Cervical cancer is the 18th most common cause of cancer mortality in women, accounting for
220 deaths in 1999. The age-standardised mortality rate from cervical cancer declined in the
target age group from 4.7 per 100,000 women to 2.0 per 100,000 women between the years
1990 and 1999. During the same period the age-standardised mortality rate for all ages also
declined from 5.0 per 100,000 women to 2.5 per 100,000 women.
• Women in the target age group from remote locations experienced a relatively high mortality
rate from cervical cancer (4.7 per 100,000 women); this compared with 2.4 deaths per 100,000
women for metropolitan and rural locations. However, between the periods 1996-1998 and
1997-1999, the age-standardised cervical cancer mortality rate declined in all locations
(metropolitan, rural and remote).
• Only Western Australia, South Australia and the Northern Territory have Indigenous mortality
registration data of sufficient quality to be publishable. For these jurisdictions, in the period
from 1997-1999 there were 13 deaths (an age-standardised mortality rate of 15.8 per 100,000
xiv
women) from cervical cancer among Indigenous women in the target age group. This is over
seven times the corresponding rate in non-Indigenous women (2.2 per 100,000 women). It
does indicate a decline in mortality compared with the 1996-1998 mortality rate for
Indigenous women in the target age group, which was 19.0 per 100,000 women. However,
these rates are based on relatively small numbers of cases and may be subject to large
variability. Despite the relatively large size of the apparent decline in the rate, it is still within
the range of variation that would be expected due to chance, that is, it is not statistically
significant.
xv
National Cervical Screening Program
The National Cervical Screening Program continues to be a vibrant component of women’s
health in Australia. Cervical screening has been available in Australia for more than 35 years.
Many women have grown up with the Program and regard a regular Pap smear as an integral
aspect of their personal health care. This year we are able to show that, among women aged
20-69 years, the mortality rate from cervical cancer had declined by over 55% between 1989 and
1999. This is a remarkable achievement for any cancer over such a short time period. This
achievement stands as a testimony to the commitment of women, health providers and
government to the Program.
The National Advisory Committee continues to meet twice per year, with many of its members
also contributing to the Working Groups. A new Working Group, the Aboriginal and Torres Strait
Islander Women’s Forum, was established during 2000. The incidence and mortality from
cervical cancer among Aboriginal and Torres Strait Islander women continues to be unacceptably
high. The Forum will allow for a more concentrated effort to reduce this burden to be made at the
national level. The Chair of the Forum is Ms Patricia Kurnoth.
The other four Working Groups continue.
The Education, Communication and Recruitment Working Group is developing national
resources for women and health practitioners about early rescreening. These resources will
include information on underscreening. Although early rescreening is a problem in many
countries, Australia is one of the first countries to tackle the issue formally. Thus our
achievements in this area could have both national and international benefit.  This Working
Group is chaired by Ms Sue Gilchrist.
The New Technologies Working Group maintains a watching brief on research, both within
Australia and internationally, into new approaches to preventing cervical cancer. Given the large
policy implications of adopting new technologies, high-quality evidence will be needed before
changes are made. Mr Robert  Rome is the Chair.
The Policy and Cost-Effectiveness Working Group is now well advanced in reviewing the
screening policy. Particular emphasis is being given to the age range and the recommended
rescreening interval. A review of the National Health and Medical Research Council’s
‘Guidelines for the Management of Women with Screen Detected Abnormalities’ is planned to
begin later this year.  The Chair of the Working Group is Ms Jennifer Muller.
The Quality Assurance Working Group, chaired by Dr Annabelle Farnsworth, continues work on
the Performance Standards for Laboratories Reporting Cervical Cytology. Compliance with the
Standards has been mandatory for laboratory accreditation since 1 July 1999. Survey instruments
have been completed for a study of the quality of reporting of cervical histopathology by
Australian laboratories. This study will complement our understanding of pathology laboratory
services for the cervical health of women.
This third annual report of key performance indicators for the National Cervical Screening
Program is particularly welcomed. The Report’s usefulness to the Program and its accountability
to the community, to health professionals and to Government make it a valued publication.
Dr Heather Mitchell
Chair
National Advisory Committee to the
National Cervical Screening Program
1Cervical screening
The National Cervical Screening Program in Australia
In 1986 the World Health Organization and the International Agency for Research on Cancer
published guidelines outlining the essential features of cervical screening programs. These
guidelines were subsequently used as the basis for a review of existing cervical screening in
Australia. Between 1988 and 1990, a Program evaluation was undertaken by the Cervical
Screening Evaluation Steering Committee at the then Australian Institute of Health on behalf of
the Australian Health Ministers’ Advisory Council (AHMAC).
In its report to AHMAC, the Committee recommended the introduction of an organised
approach to cervical screening, including the establishment of State and Territory registries to
provide the infrastructure for this process. A major recommendation was that registries should:
• remind women to attend for screening;
• provide a fail-safe system to ensure the follow-up of women with significantly abnormal Pap
smears;
• provide individual women’s cervical screening histories to laboratories and clinicians to aid
reporting and management; and
• monitor the effects of initiatives to improve participation by women in screening (AHMAC
1991).
The current Australian policy is for all women who have been sexually active at any stage in
their lives to have a Pap smear every two years until age 70 years. Pap smears may cease at the
age of 70 years for women who have had two normal Pap smears within the last five years.
Women over 70 years who have never had a Pap smear, or who request a Pap smear, should be
screened.
The Program seeks to reduce morbidity and mortality from cervical cancer by:
• maximising participation by eligible women in routine 2-yearly screening;
• encouraging practitioners to collect cervical smears containing adequate samples of cervical
cells;
• instituting a uniform and reliable reporting system;
• developing appropriate evaluation and management protocols for women with screen-detected
abnormalities; and
• promoting effective treatment and follow-up for women with screen-detected abnormalities of
significant malignant potential (DHSH 1994a).
Recruitment
State and Territory Programs actively recruit women in the target screening age group
20-69 years by a range of strategies including health promotion activities and direct mailouts
based on local electoral rolls. Other mechanisms include providing reminder services for women
who do not otherwise attend for rescreening, and providing a back-up service encouraging
women with significantly abnormal smears to be followed up. This work is facilitated by
State- and Territory-based cervical cytology registries.
2Cervical cytology registers
Cervical cytology registers operate in all States and Territories, and maintain information about
women and their screening history on a confidential basis. In all jurisdictions, cervical cytology
registers are covered by State and Territory legislation. Registration on cervical cytology
registers is voluntary, and women may opt not to be included. Doctors or health workers are
required to advise women about information sent to the cervical cytology registers.
If the woman does not object, her demographic details, together with a summary of the smear
report, are forwarded by the pathology laboratory to the cervical cytology register located in the
State or Territory. If a woman has chosen to opt for non-inclusion, her data are still included on
the register in some States for statistical purposes but are unidentified, and by definition no
follow-up is possible. It is estimated that 1-3% of women choose not to be included on the
register.
Table 1: State and Territory registry commencement dates
State or Territory Commencement date
New South Wales Pap Test Register July 1996
Victorian Cervical Cytology Registry November 1989
Queensland Health Pap Smear Register February 1999
Cervical Cytology Registry of Western Australia July 1992
South Australian Cervix Screening Program June 1993
Tasmanian Cervical Cytology Register May 1994
Australian Capital Territory Cervical Cytology Register March 1995
Northern Territory Pap Smear Register March 1996
Reminders
If the cytology report shows no abnormal cells (that is, a negative smear), the national screening
policy recommends a repeat smear in two years. A reminder notice is sent to women if they have
not attended for screening for more than two years; however, the time at which the reminder
notice from the cervical cytology register is dispatched varies from 27 to 36 months across the
States and Territories. If a woman’s Pap smear is abnormal, the registries observe follow-up
protocols involving letters to doctors and to women to try to ensure that women with
abnormalities are being appropriately followed up.
3National cervical screening
monitoring indicators
This report focuses on monitoring the performance of the National Cervical Screening Program.
Indicators are used as summary measures of program activity, performance and outcome.
Indicators such as those described below help measure changes in disease patterns and examine
the contribution that health interventions might have in preventing or reducing mortality. While
indicators can be used in the evaluation of screening or other health interventions, they typically
relate to the effect of the intervention at a broad level. Indicators are generally not designed to
focus on processes or particularly detailed operations.
Screening indicators for the National Cervical Screening Program cover the areas of
participation, early rescreening, detection of low- and high-grade abnormalities, incidence, and
mortality. These indicators have been recommended by the National Screening Information
Advisory Group, and endorsed by the National Advisory Committee and State and Territory
cervical screening programs. Indicators are reviewed annually. No changes have been made to
the existing indicators for reporting in 1998-99.
An overview of each indicator’s intention, application and definition is given in the following
pages. The overview is supported with data showing the current status and trend of the indicator.
Additional information has been provided as background material to interpret the indicators, and
to assist those not familiar with this area of population health.
Indicator 1: Participation rate for cervical screening
Percentage of women screened in a 24-month period by 5-year age groups (20-24, 25-29, 30-34,
35-39, 40-44, 45-49, 50-54, 55-59, 60-64, 65-69, 70-74, 75-79, 80-84, 85+) and for the target age
group (20-69 years).
Indicator 2: Early rescreening
Proportion of women rescreened by number of rescreens during a 24-month period following a
negative smear.
Indicator 3: Low-grade abnormality detection
Number of women with a histologically verified low-grade intraepithelial abnormality detected
in a 12-month period as a ratio of the number of women with a histologically verified high-grade
intraepithelial abnormality detected in the same period.
Indicator 4: High-grade abnormality detection
Detection rate for histologically verified high-grade intraepithelial abnormalities per 1,000
women screened in a 12-month period by 5-year age groups (20-24, 25-29, 30-34, 35-39, 40-44,
45-49, 50-54, 55-59, 60-64, 65-69, 70-74, 75-79, 80-84, 85+) and for the target age group
(20-69 years, age-standardised).
4Indicator 5: Incidence of micro-invasive cervical cancer
Incidence rates of micro-invasive cervical cancer per 100,000 estimated resident female
population in a 12-month period by 5-year age groups (20-24, 25-29, 30-34, 35-39, 40-44, 45-49,
50-54, 55-59, 60-64, 65-69, 70-74, 75-79, 80-84, 85+) and for the target age group (20-69 years,
age-standardised).
Indicator 6: Incidence of squamous, adenocarcinoma,
adeno-squamous and other cervical cancer
Incidence rates of squamous, adenocarcinoma, adeno-squamous and other cervical cancer per
100,000 estimated resident female population in a 12-month period by 5-year age groups (20-24,
25-29, 30-34, 35-39, 40-44, 45-49, 50-54, 55-59, 60-64, 65-69, 70-74, 75-79, 80-84, 85+) and
for the target age group (20-69 years, age-standardised).
Indicator 7: Mortality
Mortality rates from cervical cancer per 100,000 estimated resident female population in a
12-month period by 5-year age groups (20-24, 25-29, 30-34, 35-39, 40-44, 45-49, 50-54, 55-59,
60-64, 65-69, 70-74, 75-79, 80-84, 85+) and for the target age group (20-69 years,
age-standardised).
Periodic indicators
Periodic indicators have been developed to report on issues that are of importance in monitoring
the outcomes of the cervical screening Program over a longer period of time than one year. This
longer period allows for a greater aggregation of information on issues that are subject to wide
annual fluctuations, and allows for a more confident and meaningful estimate of the outcomes.
The periodic indicators presented in this report are based on a reporting period of three years.
Periodic incidence and mortality indicators by location
Indicator 8: Incidence by location
Incidence rates of cervical cancer per 100,000 estimated resident female population in a 3-year
period by location and 5-year age groups (20-24, 25-29, 30-34, 35-39, 40-44, 45-49, 50-54,
55-59, 60-64, 65-69, 70-74, 75-79, 80-84, 85+) and for the target age group (20-69 years,
age-standardised).
Indicator 9: Mortality by location
Mortality rate from cervical cancer per 100,000 estimated resident female population in a 3-year
period by location and 5-year age groups (20-24, 25-29, 30-34, 35-39, 40-44, 45-49,
50-54, 55-59, 60-64, 65-69, 70-74, 75-79, 80-84, 85+) and for the target age group (20-69 years,
age-standardised).
Postcode and statistical local area information for incidence and mortality is routinely collected
at the point of diagnosis or death. These data have been classified using the Rural, Remote and
Metropolitan Areas classification (RRMA). This classification was developed in 1994 by the
then Department of Primary Industries and Energy and the then Department of Human Services
and Health as a framework by which various data sources could be analysed for metropolitan,
5Table 2: Structure of the Rural, Remote and Metropolitan Areas classification
Zone Category
Metropolitan zone Capital cities
Other metropolitan centres (urban centre population >100,000)
Rural zone Large rural centres (urban centre population 25,000-99,999)
Small rural centres (urban centre population 10,000-24,999)
Other rural areas (urban centre population <10,000)
Remote zone Remote centres (urban centre population >5,000)
Other remote area (urban centre population <5,000)
Source: DPIE & DHSH 1994.
rural and remote zones. The RRMA groups are classified according to Statistical Local Area
based on the Australian Standard Geographical Classification (ASGC) version 2.1 (DPIE &
DHSH 1994). Concordance algorithms have been developed to convert statistical local area
information coded according to earlier and later ASGC versions into rural, remote and
metropolitan area groupings.
Indicator 10: Indigenous mortality
Mortality rates from cervical cancer per 100,000 estimated resident female population in a 3-year
period by Indigenous status and 5-year age groups (20-24, 25-29, 30-34, 35-39, 40-44, 45-49,
50-54, 55-59, 60-64, 65-69, 70-74, 75-79, 80-84, 85+) and for the target age group (20-69 years,
age-standardised).
This indicator examines the patterns of mortality among Indigenous women.
Identification of Indigenous status is still very fragmented and generally of poor quality in health
data collections, and cervical screening data are no exception. Of the seven cervical screening
indicators, only one indicator can be stratified by Indigenous status: mortality. Even for this,
coverage is not complete. Only Western Australia, South Australia and the Northern Territory are
currently considered to have adequate coverage of Indigenous mortality in the registration of
deaths. Therefore, mortality data from these States and Territory only are analysed in this report.
Confidence intervals
Where indicators include a comparison between States and Territories, between time periods,
between geographic location or between Indigenous and non-Indigenous women, a 95%
confidence interval (CI) is presented along with the rates. This is because the observed value of a
rate may vary due to chance even where there is no variation in the underlying value of the rate.
The 95% confidence interval represents a range over which variation in the observed rate is
consistent with this chance variation. These confidence intervals can be used as an approximate
test of whether changes in a particular rate are consistent with chance variation. Where the
confidence intervals do not overlap, the change in a rate is greater than that which could be
explained by chance. Where the intervals overlap, changes in the rate may be taken as
approximately consistent with variability due to chance.
For example, the participation rate for Victoria in 1997-1998 was 67.8% with a confidence
interval of 67.7% to 68.0%. The corresponding rate for 1998-1999 was 68.9% with a confidence
interval of 68.8% to 69.0%. These two intervals do not overlap, so the difference between the
1997-1998 and 1998-1999 rates is larger than would be expected due to chance alone.
6Another example is the comparison between cervical cancer mortality rates for women living in
rural and remote areas. In the period 1997-1999 there were 2.4 cervical cancer deaths per
100,000 women living in rural areas. This rate had a confidence interval of 2.0 to 2.9. The
corresponding rate for women in remote areas was 4.7 per 100,000 women, with a confidence
interval of 2.8 to 7.0. These confidence intervals overlap and so, despite the relatively large
difference between the two observed rates, they are still consistent with chance variation. This
arises from the fact that remote areas of Australia have small populations, which leads to small
numbers of deaths from any specific cause, and these small numbers may fluctuate from year to
year. This in turn leads to relatively wide confidence intervals for an observed mortality rate.
It is important to note that this result does not imply that the difference between the two rates is
definitely due to chance. Instead, an overlapping confidence interval represents a difference in
rates that is too small to allow us to differentiate between a real difference and one which is due
to chance variation.
7Participation
The major objective of the National Cervical Screening Program is to reduce morbidity and
mortality from cervical cancer by detecting treatable pre-cancerous abnormalities before a
progression to cancer. Through increased participation, more women with pre-cancerous
abnormalities can be detected and treated before progression to cervical cancer occurs, thus
reducing morbidity to women. Also, increased participation will lead to the detection of more
women with early stages of cancer where treatment can reduce mortality.
Through a variety of recruitment initiatives, the Program actively targets women in the age group
20-69 years. The recommended screening interval for women in the target age group 20-69 years
who have ever been sexually active at any stage in their lives is two years. Pap smears may cease
at the age of 70 years for women who have had two normal Pap smears within the last five years.
Women over 70 years who have never had a Pap smear, or who request a Pap smear, should be
screened.
Some women in the target population are unlikely to require screening, such as:
• those who have had a total hysterectomy with their cervix removed;
• those who have never been sexually active; and
• women with a previously diagnosed gynaecological cancer (this last group is monitored under
a clinical arrangement) (Snider & Beauvais 1998).
In principle, the denominator and numerator should be adjusted to remove all of the above three
groups from the data on participation. However, in practice, the data are adjusted to remove
women who have had a hysterectomy but the latter two groups cannot be adjusted for, due to
methodological difficulties.
State and Territory Programs have strategic plans in place to increase women’s participation in
cervical screening. Such strategies include targeting priority population groups including
Indigenous women, rural and remote women, and women from culturally and linguistically
diverse backgrounds.
The objective, measurement and usefulness of participation as an indicator is outlined below:
• the participation indicator measures the proportion of the target population covered by the
National Cervical Screening Program and the current screening policy of a 2-yearly interval;
• this indicator is important in assessing the contribution of the National Cervical Screening
Program to changes in incidence and mortality. The indicator can also be used as a means of
evaluating recruitment practices, particularly if participation rates are analysed by
demographic characteristics; and
• when this indicator is used in conjunction with others, it can be used to support debate relating
to target groups and screening intervals.
The data presented for this indicator refer to the 2-year period 1998-1999. Data for the period
1997-1998 are included for comparison.
8State- and Territory-specific issues
The Queensland Health Pap Smear Register began its operation in February 1999. Therefore
participation data are not available for this jurisdiction. The overall rate for Australia for this
indicator has been calculated excluding the Queensland population for the respective years.
Except for Western Australia and the Australian Capital Territory, the participation rates are
based on all women who were screened in that State or Territory. This may lead to an
overestimation of the numbers of women screened because of double counting of some women
between States and Territories. This may be the result of difficulty in identifying State or
Territory of residence for women in border areas and the inclusion of women resident overseas.
9Indicator 1: Participation rate for cervical screening
Percentage of women screened in a 24-month period by 5-year age groups (20-24, 25-29,
30-34, 35-39, 40-44, 45-49, 50-54, 55-59, 60-64, 65-69, 70-74, 75-79, 80-84, 85+) and for the
target age group (20-69 years).
The graphs and tables below refer to the data for the target age group only. For detailed data
refer to Tables 1b and 2b (pages 43 and 45).
Notes
1. Participation rates have been adjusted for the estimated proportion of women who have had a hysterectomy.
2. The Queensland Health Pap Smear Register commenced February 1999, therefore no data are available for
this report.
Source: AIHW analysis of State and Territory Cervical Cytology Registry data.
Figure 1: Participation rates in the National Cervical Screening Program by age group,
Australia, 1997-1998 and 1998-1999
Age group
2-year
period 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 20-69
(Per cent)
1997-1998 50.6 65.5 69.0 70.7 69.8 69.4 72.5 62.9 54.9 43.4 63.9
1998-1999 52.0 66.0 69.7 71.4 70.9 69.9 72.8 63.9 57.4 45.2 64.8
• The age-standardised (AS) participation rate for cervical screening (excluding Queensland) for
the period January 1998 to December 1999 was 64.8% for the target population of women
aged 20-69 years (Table 2b, page 45).
• During this period 2,777,324 women were screened in Australia for pre-cancerous changes to
cervical cells. Of these 2,716,364 (97.8%) were in the target age group 20-69 years of age
(Table 2a, page 44).
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• There was considerable variation in the rate of participation of different age groups within the
target age group, ranging from a peak of 73% participation in the 50-54 years age group to a
low of 45% in the 65-69 years age group (Table 2b, page 45).
• There was a small increase in the participation rate in most 5-year age groups within the target
age group between the two periods 1997-1998 and 1998-1999. This resulted in 62,860 more
women in the target age group being screened in 1998-1999. During the same period,
participation of women in the 60-64 years age group had the largest increase of approximately
4.6% (Tables 1a to 2b, pages 42-45).
Notes
1. The Queensland Health Pap Smear Register commenced February 1999, therefore no data are available
for this report.
2. Rates are expressed as the percentage of the eligible female population and age standardised to the
Australian 1991 population.
3. Bars on graphs represent 95% confidence intervals.
Source: AIHW analysis of State and Territory Cervical Cytology Registry data.
Figure 2: Participation (age-standardised) in the National Cervical Screening Program by
women aged 20-69 years, by States and Territories, 1997-1998 and 1998-1999
2-year period/
rate NSW Vic WA(a) SA Tas ACT(a) NT Australia
1997-1998
AS rate 59.4 67.8 65.7 66.7 66.9 67.0 62.0 63.9
CI 59.3-59.5 67.7-68.0 65.4-65.9 66.5-67.0 66.5-67.3 66.5-67.6 61.3-62.7 63.8-63.9
1998-1999
AS rate 60.8 68.9 65.4 67.6 66.3 67.6 64.5 64.8
CI 60.7-60.9 68.8-69.0 65.1-65.6 67.3-67.8 65.8-66.7 67.0-68.1 63.7-65.3 64.8-64.9
(a) The WA and ACT registers only include women with a valid WA or ACT address respectively.
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• The registers in New South Wales, South Australia, Tasmania and Northern Territory record
Pap smears for a small number of women who live outside the State or Territory. Of these,
South Australia had the highest proportion of registrations for interstate residents in
1998-1999 (1.0% of all Pap smears).
• In 1998-1999 there was considerable variation in the participation rates between States and
Territories for women in the target age group 20-69 years, ranging from a high of 68.9% in
Victoria to a low of 60.8% in New South Wales (Table 2b, page 45).
• The participation rate in all States and Territories except Western Australia and Tasmania
increased between the two periods 1997-1998 and 1998-1999. The Northern Territory
registered the largest percentage increase between the two periods (4.0%). Apart from the
Australian Capital Territory, the increase in participation in these jurisdictions was greater than
would have been expected by chance (Tables 1b and 2b, pages 43 and 45).
12
13
Early rescreening
The National Cervical Screening Program seeks to maximise reductions in incidence of and
mortality from cervical cancer. The design of the Program defines two key parameters to achieve
these objectives: target populations and screening intervals. Compliance with these parameters is
crucial in maintaining the effectiveness of the Program and in maintaining cost efficiency in
order that resources may be used to increase coverage of the population. For most women who
have a negative smear, the recommended interval until their next Pap smear is two years.
This indicator:
• tracks over a period of 24 months a cohort of women from all States and Territories, except
Queensland, who had a negative smear result in February 1998, to determine the extent of
early rescreening within the Program. February was selected as the index month because it has
been shown to be a relatively stable month in terms of the number of women who are
screened. This pattern has been consistent over a number of years, possibly because fewer
women take holidays at this time; and
• measures the compliance with the recommended screening interval following a negative
smear, and the range of screening practices around it.
The indicator is important in assessing screening coverage around the recommended interval, as
significant differences may reduce the Program’s effectiveness.
The results presented here are based on data for the 2-year period from February 1998. For
comparison, data from February 1997 are also presented.
This indicator should be interpreted with caution as:
• women attending for a 2-year rescreen will do so at a time convenient to them. Often this can
be combined with a visit to a general practitioner in the period immediately before the 2-year
anniversary. Some prescriptions for oral contraceptives will lapse at 22 months and often the
appointment for a new script is combined with a Pap smear; and
• some early rescreening after a negative Pap smear report is appropriate and in accordance with
the guidelines of the National Health and Medical Research Council (NHMRC). Specifically,
if a woman has a history of histologically proven high-grade abnormality, annual screening is
recommended. If a woman is being monitored after treatment or during the resolution phase of
a low-grade abnormality, it is appropriate for her to be screened earlier than the 24-month
interval.
In light of these points, this indicator is currently under review and may change in future.
14
Indicator 2: Early rescreening
Proportion of women rescreened by number of rescreens during a 24-month period
following a negative smear.
Refer to Table 4 (page 46).
Notes
1. The reference period for this indicator was the 24 months following February 1998.
2. The Queensland Health Pap Smear Register commenced February 1999, therefore no data are available
for this report.
Source: AIHW analysis of State and Territory Cervical Cytology Registry data.
Figure 3: Proportion of women rescreened by number of screens during the
24-month period following a negative smear in February 1997 and 1998, Australia
• In this indicator, a cohort of 138,490 women from all States and Territories, except
Queensland, who had a negative smear result in February 1998, was tracked over a period of
24 months (Table 3, page 46).
• Approximately 57% of women who had a Pap smear in February 1998 were not rescreened in
the following two years. However, 35% of all screened women had one additional smear, 7%
had two additional smears, and less than 2% had three or more additional smears (Table 4,
page 46).
• Overall, the percentage of women who did not have any additional smears following a
negative smear increased by 6.6% between the 1997 (53.3%) and 1998 (56.8%) cohorts. The
percentage of women who had one additional smear declined by 6.7%; for two additional
smears the reduction was 9.2%. The percentage of women who had three or more smears
declined by 21.0% (Table 4, page 46).
2-year period 0 screens 1 screen 2 screens 3+ screens
(Per cent)
1997-1998 53.3 37.2 7.6 1.9
1998-1999 56.8 34.7 6.9 1.5
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Percentage of women
Refer to Table 4 (page 46).
Notes
1. The reference period for this indicator was the 24 months following February 1998.
2. The Queensland Health Pap Smear Register commenced February 1999, therefore no data are available
for this report.
Source: AIHW analysis of State and Territory Cervical Cytology Registry data.
Figure 4: Proportion of women rescreened by number of screens during the 24-month
period following a negative smear in February 1998, by States and Territories
• More than 60% of women from South Australia, Tasmania, the Australian Capital Territory
and the Northern Territory, who had a negative screen in February 1998, had no further
screens in the following 24 months (Table 4, page 46).
• There was some variation in the proportion of early rescreens by State and Territory. The
percentage of women who had one repeat smear ranged from 20.8% (Australian Capital
Territory) to 36.7% (Western Australia). The proportion of women who had two or more
repeat screens varied between States and Territories, from 3.4% in the Australian Capital
Territory to 10.3% in Victoria (Table 4, page 46).
No. of
screens NSW Vic WA SA Tas ACT NT Australia
(Per cent)
0 screens 57.5 53.7 54.9 60.6 60.1 75.9 65.4 56.8
1 screen 34.8 36.0 36.7 32.5 32.9 20.8 27.8 34.7
2 or more 7.7 10.3 8.4 7.0 7.0 3.4 6.8 8.4
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Low-grade abnormalities
The Pap smear test is able to identify a range of abnormalities in cervical cells. Some of these
abnormalities (the so-called high-grade abnormalities) have a greater chance of becoming
malignant, and are therefore treated aggressively. The chance of low-grade abnormalities
progressing to malignant change is very much less. However, once they are identified on biopsy
the option of active treatment is available.
In this report a low-grade intraepithelial abnormality includes:
• atypia;
• warty atypia (human papilloma virus (HPV) effect);
• possible cervical intraepithelial neoplasia (CIN) (see Glossary);
• equivocal CIN;
• CIN 1; or
• endocervical dysplasia not otherwise specified (NOS).
The indicator is measured as the ratio of histologically verified low-grade intraepithelial
abnormalities detected to histologically verified high-grade intraepithelial abnormalities.
The purpose of screening is to reduce morbidity by identifying pre-cancerous abnormalities.
Effective treatment of these abnormalities prevents invasive cancer and hence avoids the
morbidity associated with cancer treatment.
The rationale behind this indicator is to provide a broad indication of the extent to which
screening exposes women taking part in the Program to the risk of adverse outcomes without an
associated health benefit.
A biopsy is a relatively invasive procedure in which a piece of tissue is taken from the cervix,
and represents an increased risk of morbidity for a woman compared with having a Pap smear.
This indicator provides data about the number of women who have a biopsy that finds only a
low-grade abnormality with a low risk of progression to invasive cancer, and compares it with the
number of women who have a high-grade abnormality.
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Indicator 3: Low-grade abnormality detection
Number of women with a histologically verified low-grade intraepithelial abnormality
detected in a 12-month period as a ratio of the number of women with a histologically
verified high-grade intraepithelial abnormality detected in the same period.
Refer to Tables 5a and 5b (page 47).
Notes
1. The ACT did not collect histology details during 1998.
2. The Queensland Health Pap Smear Register commenced February 1999, therefore no data are
available for this report.
Source: AIHW analysis of State and Territory Cervical Cytology Registry data.
Figure 5: Ratio of low- to high-grade abnormalities by women aged 20-69 years, by
States and Territories, 1998 and 1999
Year NSW Vic WA SA Tas ACT NT Australia
(Ratio)
1998 1.5 1.1 1.5 1.5 1.4 n.a. 0.9 1.4
1999 1.4 1.2 1.7 1.4 1.4 1.2 0.9 1.4
• The ratio of histologically confirmed low-grade abnormalities to high-grade abnormalities was
1.4 for Australia in 1999, the same as in 1998. Note that the 1998 ratio does not include data
for the Australian Capital Territory (Tables 5a and 5b, page 47).
• In 1999 there was some variation among States and Territories, with the highest ratios in
Western Australia (1.7), followed by South Australia, New South Wales and Tasmania (1.4),
while the Northern Territory (0.9) had the lowest ratio (Table 5b, page 47).
• Between 1998 and 1999, there were small shifts in the ratio of low-grade intraepithelial
abnormalities to high-grade intraepithelial abnormalities detected within States and the
Northern Territory. The ratios in New South Wales and South Australia declined, while there
was a small increase in the ratio in Victoria and Western Australia (Tables 5a and 5b, page 47).
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High-grade abnormalities
High-grade abnormalities have a greater probability of progressing to invasive cancer than low-
grade abnormalities. Therefore, one of the aims of the National Cervical Screening Program is to
set a screening interval which detects most of these abnormalities before they progress and
become invasive. This indicator measures the frequency of this type of abnormality in the
screened community. A high-grade intraepithelial abnormality is defined in this report as
CIN 1/2, CIN 2, CIN 3 or adenocarcinoma in situ.
The NHMRC has produced guidelines to assist in the management of women who have low- and
high-grade intraepithelial abnormalities (DHSH 1994b).
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• The age-standardised detection rate for histologically verified high-grade intraepithelial
abnormalities increased from 6.7 per 1,000 women screened in the target age group 20-69
years in 1998 to 7.6 per 1,000 women screened in 1999 (Tables 9a and 9b, page 54).
• In 1999, of the 1,582,012 women screened in the target age group 20-69 years in Australia,
11,686 (0.7%) histologically verified high-grade abnormalities were detected (Tables 7b and
8b, pages 51 and 53).
• The rate of histologically verified high-grade intraepithelial abnormalities was much higher in
the younger age groups (Figure 6). In 1999, the rate in the 20-24 year age group was 16.8 per
1,000 women screened compared with 2 or less per 1,000 women in the age groups from 50-
54 to 65-69. This age-specific distribution contrasts with patterns of cervical cancer incidence
and mortality that are the inverse of this age distribution. This suggests that the malignant
potential of an intraepithelial high-grade abnormality is greater with increasing age.
Indicator 4: High-grade abnormality detection
Detection rate for histologically verified high-grade intraepithelial abnormalities per 1,000
women screened in a 12-month period by 5-year age groups (20-24, 25-29, 30-34, 35-39,
40-44, 45-49, 50-54, 55-59, 60-64, 65-69, 70-74, 75-79, 80-84, 85+) and for the target age
group (20-69 years, age-standardised).
The graph and table below refer to the data for the target age group only. For detailed data
refer to Tables 6a and 6b (pages 48 and 49).
Note: The Queensland Health Pap Smear Register began in February 1999; therefore no data are available for
this report.
Source: AIHW analysis of State and Territory Cervical Cytology Registry data.
Figure 6: High-grade abnormalities per 1,000 women by age group, Australia, 1998 and 1999
Age group
Age 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 20-69
(Number per 1,000 women)
1998 14.3 13.9 8.8 6.3 4.1 2.6 1.9 1.6 1.7 1.0 6.7
1999 16.8 15.0 10.0 6.7 4.4 3.2 2.0 1.7 1.6 2.0 7.6
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Refer to Tables 9a and 9b (page 54).
Notes
1. The Queensland Health Pap Smear Register began in February 1999; therefore no data are available
for this report.
2. The ACT did not collect histology data during 1998.
3. Rates are standardised to the 1991 Australian total population.
4. Bars on graphs represent 95% confidence intervals.
Source: AIHW analysis of State and Territory Cervical Cytology Registry data.
Figure 7: Age-standardised rate of high-grade abnormalities per 1,000 women
screened aged 20-69 years, by States and Territories, 1998 and 1999
NSW Vic WA SA Tas ACT NT Australia
AS rate 1998 6.3 5.8 6.7 9.5 10.5 n.a. 13.3 6.7
95% CI 6.1-6.5 5.5-6.0 6.4-7.1 9.0-10.1 9.7-11.4 n.a. 11.7-14.9 6.6-6.9
AS rate 1999 7.7 6.9 7.7 8.5 9.9 6.8 8.7 7.6
95% CI 7.4-7.9 6.7-7.2 7.4-8.2 8.0-9.0 9.0-10.9 5.8-7.7 7.4-10.2 7.4-7.7
• In 1998 and 1999 there was considerable variation in the State and Territory age-standardised
rate of high-grade abnormalities per 1,000 women screened. In 1999, Tasmania had the
highest rate at 9.9 per 1,000 women screened, and the Australian Capital Territory the lowest
at 6.8 per 1,000 women in the target age group 20-69 years (Tables 9a and 9b, page 54).
• The age-standardised rate of high-grade abnormalities per 1,000 women increased in New
South Wales (from 6.3 to 7.7), Victoria (from 5.8 to 6.9) and Western Australia (6.7 to 7.7)
between 1998 and 1999. The increase in all three jurisdictions was statistically significant.
• A statistically significant decline in the age-standardised rate of high-grade abnormalities per
1,000 women was observed in the Northern Territory (from 13.3 to 8.7) between 1998 and
1999. During the same period, South Australia and Tasmania also showed a decrease;
however, the decline was not statistically significant (Tables 9a and 9b, page 54).
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Incidence
A major objective of the National Cervical Screening Program is to reduce the incidence of
cervical cancer by detecting treatable pre-cancerous abnormalities before their progression to
cancer. However, where these pre-cancerous abnormalities cannot be detected, diagnosis of
cancer at its earliest stage, the micro-invasive stage, is the best alternative. The next two
indicators measure the incidence rates of micro-invasive and all cervical cancers in the
community.
There are several forms of cervical cancer. The greatest proportion of cervical cancers are
squamous cell carcinomas. Squamous cell carcinoma of the cervix is preceded, over a period of
years, mostly by a spectrum of asymptomatic abnormalities. CIN usually occurs at least a decade
before cervical cancer. If CIN remains untreated, some women will develop cervical cancer.
In 1994 the International Federation of Gynaecology and Obstetrics endorsed the following
definition of micro-invasive carcinoma of the cervix:
Stage 1a1 Measured invasion of stroma no greater than 3 mm in depth and no wider than 7 mm.
Stage 1a2 Measured invasion of stroma greater than 3 mm and no greater than 5 mm in depth
and no wider than 7 mm. The depth of invasion should not be more than 5 mm taken
from the base of the epithelium, either surface or glandular, from which it originates.
Vascular space involvement, either venous or lymphatic, should not alter the staging
(Ostor & Mulvany 1996).
Micro-invasive squamous cell carcinoma is the most common form of micro-invasive cancer, and
is reported in Indicator 5. There are also other forms of micro-invasive cancer for which data are
not available.
Looking at cervical cancer overall, there has been a considerable reduction in the incidence
(35%) since 1987. Cervical screening has been available on an ad hoc basis since the 1960s, but
it is only since the late 1980s and early 1990s that there has been an organised national approach
to screening at a population level. For this report, the most recent national data available on
incidence are for 1998, in contrast to screening data, which are available for 1999. This time lag
in availability of incidence data is expected to reduce over the next few years as State and
Territory cancer registries implement strategies to reduce data-processing backlogs.
24
Indicator 5: Incidence of micro-invasive cervical
cancer
Incidence rates of micro-invasive squamous cell carcinoma per 100,000 estimated resident
female population in a 12-month period by 5-year age groups (20-24, 25-29, 30-34, 35-39,
40-44, 45-49, 50-54, 55-59, 60-64, 65-69, 70-74, 75-79, 80-84, 85+) and for the target age
group (20-69 years, age-standardised).
The graphs and tables below refer to the data for the target age group only. For detailed data
refer to Table 11 (page 56).
Note: Rates are expressed per 100,000 women and age standardised to the Australian 1991 population.
Source: National Cancer Statistics Clearing House (AIHW).
Figure 8: Age-standardised incidence rates for micro-invasive squamous cell cancer,
women aged 20-69 years, Australia, 1987-1998
1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998
(Number per 100,000 women)
AS rate 1.8 1.7 1.7 2.6 2.9 2.7 2.4 3.0 3.1 2.5 2.0 1.9
• The age-standardised incidence rate of micro-invasive cervical cancer was 1.8 per 100,000
women for all women in 1998, and 1.9 per 100,000 for the target age group 20-69 years (Table
11, page 56).
• In 1998 there were 122 new cases of micro-invasive cervical cancer among women of all ages,
and for the target age group 20-69 years there were 116 new cases (Table 10, page 55).
• The age-standardised incidence rates for micro-invasive squamous cell carcinoma of the cervix
have fluctuated during the period 1987-1998. Note that the number of cases of micro-invasive
cancer is very low and the rates are therefore unstable (Table 11, page 56).
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Note: Rates are expressed per 100,000 women.
Source: National Cancer Statistics Clearing House (AIHW).
Figure 9: Age-specific incidence rates of micro-invasive squamous cell cancer, women
aged 20-69 years, Australia, 1997 and 1998
Age group
Year 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69
1997 0.3 1.4 3.8 3.0 3.0 1.7 1.5 1.7 1.4 0.6
1998 0.5 2.3 2.5 3.2 2.8 1.8 2.1 0.7 1.4 0.6
• In 1998, women in the age group 35-39 years had the highest incidence rate of micro-invasive
squamous cell cancer at 3.2 per 100,000 women, whereas in 1997 women in the 30-34 year
age group had the highest incidence. The rate showed a steady decline with age from the
45-49 year age group, reaching a low of 0.6 per 100,000 for the 65-69 age group. It should be
noted that the rates for age groups 50-54 and over are based on small numbers of cases (less
than 10 cases in each 5-year age group) (Tables 10 and 11, pages 55 and 56).
• In 1998, there were 24 cases of micro-invasive squamous cell cervical cancer in women aged
35-39 years. The number of micro-invasive squamous cell cervical cancers declined in most
age groups, apart from the age groups 25-29 years and 50-54 years. Once again, it should be
noted that the number of cancers in each age group is small. The number of cancers occurring
among women in each age group 55-59 years and over is less than 10 (Table 10, page 55).
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Indicator 6: Incidence of squamous, adenocarcinoma,
adeno-squamous and other cervical cancer
Incidence rates of squamous, adenocarcinoma, adeno-squamous and other cervical cancer
per 100,000 estimated resident female population in a 12-month period by 5-year age
groups (20-24, 25-29, 30-34, 35-39, 40-44, 45-49, 50-54, 55-59, 60-64, 65-69, 70-74, 75-79,
80-84, 85+) and for the target age group (20-69 years, age-standardised).
For detailed data refer to Table 13 (page 58).
Note: Rates are expressed per 100,000 women and age standardised to the Australian
1991 population.
Source: National Cancer Statistics Clearing House (AIHW).
Figure 10: Age-standardised incidence rates of cervical cancer, Australia,
1987-1998
Age 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998
(Number per 100,000 women)
All ages 13.4 12.9 12.5 12.3 12.3 11.3 11.1 12.0 10.0 9.5 8.0 8.6
20-69 years 18.0 17.7 17.2 16.8 16.5 15.3 15.1 16.1 13.3 12.8 10.8 11.5
• In 1998, the incidence rate of all cervical cancers declined to 8.6 per 100,000 women for all
women in Australia, and 11.5 per 100,000 women for the target group (Table 13, page 58).
• In 1998, cervical cancer was the 10th most frequently diagnosed new cancer in women. There
were 868 new cases of cervical cancer diagnosed in Australia in 1998, and of these 694 were
women in the target age group 20-69 years (Table 12, page 57).
• Between 1987 and 1998 the age-standardised incidence rate for cervical cancer for women of
all ages declined by 35.8%, and for the target age group by 36.1% (Table 13, page 58).
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Refer to Table 13 (page 58).
Note: Rates are expressed per 100,000 women.
Source: National Cancer Statistics Clearing House (AIHW).
Figure 11: Age-specific incidence rates of cervical cancer, Australia, 1997 and 1998
Age group
Year 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 20-69
(Number per 100,000 women)
1997 1.3 5.8 10.8 13.6 14.9 12.5 14.0 11.9 14.6 15.4 10.8
1998 2.0 6.4 12.0 13.5 14.7 16.9 11.4 12.8 14.9 17.2 11.5
• The age-specific rate of cervical cancer incidence differs from most other cancers in that it
rises rapidly in women in the young age groups; in 1998 the age-specific rate for women aged
45-49 years was 16.9 per 100,000 women. From that age, the rate declines to 11.4 at age group
50-54, then has an upward trend to 17.2 at age group 65-69.
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• There was a considerable range in the incidence of cervical cancer among States and
Territories for women aged 20-69 years. In the period 1995-1998 South Australia had the
lowest incidence at 8.4 per 100,000 women compared with the Northern Territory, which had
the highest rate of 23.2 per 100,000 women. The South Australian rate was significantly
different from all States while the Northern Territory was significantly different from all States
and the Australian Capital Territory except Tasmania (Table 15b, page 62).
• Between the two periods 1994-1997 and 1995-1998 the incidence rate declined in all States
and Territories except Tasmania. However, the decline is not statistically significant. The rate
of decrease  in Victoria, South Australia and the Australian Capital Territory was over 11%
(Tables 14b and 15b, pages 60 and 62).
Refer to Tables 14b and 15b (pages 60 and 62).
Notes
1. Rates are expressed per 100,000 women and age standardised to the Australian 1991
population.
2. Bars on graphs represent 95% confidence intervals.
Source: National Cancer Statistics Clearing House (AIHW).
Figure 12: Age-standardised cervical cancer incidence rates by women aged
20-69 years, by States and Territories, 1994-1997 and 1995-1998
NSW Vic Qld WA SA Tas ACT NT Australia
1994-1997 13.2 13.1 14.5 13.5 9.6 14.4 11.6 25.3 13.2
95% CI 12.5-14.0 12.2-14.1 13.3-15.6 11.9-15.0 8.3-11.0 11.6-17.6 8.4-15.1 16.8-33.5 12.8-13.7
1995-1998 12.3 11.4 13.3 12.4 8.4 15.6 10.3 23.2 12.1
95% CI 11.6-13.1 10.6-12.2 12.2-14.3 10.9-13.8 7.1-9.8 12.4-18.8 7.3-13.8 16.0-31.0 11.6-12.5
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Refer to Table 16b (page 63).
Note: Rates are expressed per 100,000 women and age standardised to the Australian 1991 population.
Source: National Cancer Statistics Clearing House (AIHW).
Figure 13: Age-standardised incidence rates of cervical cancer by histological type by
women aged 20-69 years, Australia, 1987-1998
Histological type 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998
Squamous 13.3 12.6 12.8 11.7 11.6 10.9 10.5 10.9 9.2 8.8 7.5 7.8
Adenocarcinoma 2.5 3.0 2.0 2.7 2.4 2.4 2.4 3.3 2.3 2.4 2.1 2.2
Adeno-squamous 0.8 0.8 0.9 0.9 0.8 0.9 0.8 0.7 0.6 0.7 0.5 0.5
Other 1.4 1.3 1.4 1.5 1.4 1.0 1.4 1.2 1.1 0.9 0.7 1.0
• In 1998, squamous cell carcinomas of the cervix accounted for approximately 68.0% of all
new cases of cervical cancer in women aged 20-69 years, adenocarcinomas 19.3%, adeno-
squamous 4.3% and a range of other mixed and unknown histologies comprised the remaining
8.4% (Table 16a, page 63).
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• In the 3-year period 1996-1998 there were 1,874 new cases (72% of all new cases) of cervical
cancer in metropolitan locations, 638 new cases (25% of all new cases) in rural locations and
77 new cases (3% of all new cases) in remote locations (Table 18, page 64).
• In the period 1996-1998, the age-standardised cervical cancer incidence rate for women in the
target age group 20-69 years was higher in remote locations (14.9 per 100,000 women) than in
metropolitan and rural locations. This difference was not statistically significant. During the
same period, the corresponding rates for cervical cancer incidence in metropolitan and rural
locations were 11.7 and 11.5 per 100,000 women respectively (Table 19, page 65).
Indicator 8: Incidence by location
Incidence rates of cervical cancer per 100,000 estimated resident female population in a
3-year period by location by 5-year age groups (20-24, 25-29, 30-34, 35-39, 40-44, 45-49,
50-54, 55-59, 60-64, 65-69, 70-74, 75-79, 80-84, 85+) and for the target age group (20-69
years, age-standardised).
The graph and table below refer to the data for the target age group only. For detailed data
refer to Table 19 (page 65).
Notes:
1. The age-standardised rates are presented as 3-year rolling blocks of data. These years were
selected to be comparable with the mortality by location indicator presented later in this report.
2. Rates are expressed per 100,000 women and age standardised to the Australian 1991
population.
3. Bars on graphs represent 95% confidence intervals.
Source: National Cancer Statistics Clearing House (AIHW).
Figure 14: Age-standardised incidence rates of cervical cancer by location by
women aged 20-69 years, Australia, 1995-1997 and 1996-1998
Metropolitan Rural Remote
1995-1997 1996-1998 1995-1997 1996-1998 1995-1997 1996-1998
AS rate 12.5 11.7 11.6 11.5 16.1 14.9
95% CI 11.9-13.0 11.1-12.2 10.6-12.5 10.6-12.6 12.2-20.1 11.1-18.4
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• The age-standardised incidence rate of cervical cancer in all locations for women aged 20-69
years declined between the periods 1995-1997 and 1996-1998. However, the decline is not
statistically significant.
Age-specific features
(Table 19, page 65)
• Very few cervical cancers occur in women under the age of 20. The incidence rate of cervical
cancer increases with age.
• Between the periods 1995-1997 and 1996-1998 age-specific rates for the incidence of cervical
cancer declined in almost all ages in metropolitan areas. However, the age pattern of cervical
cancer incidence in rural and remote areas shows fluctuations between the same periods. This
may be due to small numbers of cervical cancer occurring in these areas.
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Mortality
Cancer of the cervix is one of the few cancers for which there is an efficacious screening test for
detection of precursors of the disease at a pre-cancerous stage, and most deaths due to cervical
cancer are potentially avoidable (Marcus & Crane 1998). However, some deaths do occur and the
objective of the National Cervical Screening Program is to reduce this mortality rate.
These indicators measure the level of mortality from cervical cancer in the total female
population by age and other demographic characteristics. These indicators are important because
from them an assessment can be made of changes in mortality rates in different age groups and
particular target groups over time. However, it should be noted that changes in the mortality rates
may not be evident for a number of years following an improvement in the participation rate.
Therefore the effectiveness of this measure needs to be viewed in the longer rather than the
shorter term.
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• Cervical cancer is the 18th most common cause of cancer death in women, accounting for
220 deaths in 1999 (Table 20, page 66). The age-standardised mortality rate for all ages was
2.5 per 100,000 women in 1999. The mortality rate from cervical cancer has been declining
over time, and between 1989 and 1999 the age-standardised cervical cancer mortality rate
declined by 53% (Table 21, page 67).
• In the target age group (women aged 20-69), mortality rates have declined at approximately
the same rate as those for all ages from 4.5 per 100,000 women in 1989 to 2.0 per 100,000
women in 1999 (Table 21, page 67).
• The mortality rate from cervical cancer declined in most age groups between the years 1989
and 1999, in particular in the 30-34 age group (74%), and in the 65-69 age group (62%)
(Table 21, page 67).
Indicator 7: Mortality
Mortality rates from cervical cancer per 100,000 estimated resident female population in a
12-month period by 5-year age groups (20-24, 25-29, 30-34, 35-39, 40-44, 45-49, 50-54,
55-59, 60-64, 65-69, 70-74, 75-79, 80-84, 85+) and for the target age group (20-69 years,
age-standardised).
Refer to Table 21 (page 67).
Notes
1. Rates for all ages are based on data for women aged 20 years and over.
2. Rates are expressed per 100,000 women and age standardised to the Australian 1991
population.
Source: AIHW Mortality Database.
Figure 15: Age-standardised mortality rates from cervical cancer, Australia,
1989-1999
1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999
All ages 5.3 5.0 4.6 4.4 4.2 4.4 4.3 3.7 3.6 3.2 2.5
20-69 years 4.5 4.7 3.9 3.4 3.6 3.8 3.6 3.0 2.8 2.6 2.0
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Note: Rates are expressed per 100,000 women.
Source: AIHW Mortality Database.
Figure 16: Age-specific cervical cancer mortality rates by age group, Australia,
1988-1990 and 1997-1999
• Cervical cancer mortality rates increase with age. Very few deaths occur in women aged less
than 20 years of age (on average <1 per year). Mortality rates tend to increase gradually from
age 20-24 years through to those women in the age groups 60-plus where the rate increases
sharply.
• In the period 1997-1999, in the target age group, the age-specific mortality rate increased
gradually from a rate of 0.2 per 100,000 women in those aged 20-24 years to 7.0 deaths per
100,000 women in the 65-69 age group.
• Between 1988-1990 and 1997-1999, age-specific mortality rates have declined in all age
groups.
Age group
Period 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+
1988-
1990 0.1 0.8 2.3 3.4 4.7 7.1 5.5 7.7 9.8 13.7 14.2 15.6 16.2 21.1
1997-
1999 0.2 0.4 0.9 2.0 2.5 3.4 3.4 4.0 5.8 7.0 9.5 10.4 12.8 17.4
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• There were 1,091 deaths from cervical cancer in the States and Territories during the period
from 1996-1999. As expected, the largest number of deaths from cervical cancer were in the
most populous States of New South Wales (391) and Victoria (244) (Table 24, page 70).
• There was considerable variation in the age-standardised mortality rates for all women among
States and Territories. The Northern Territory rate (10.6 per 100,000 women) was over twice
as high as that of the next highest State, Tasmania (4.7 per 100,000 women) (Table 25, page
71).The age-standardised mortality rate for the Northern Territory reflects its high proportion
of Indigenous women. In the period 1987-1993 Indigenous women were almost 12 times more
likely to die from cervical cancer than other Northern Territory women (d’Espaignet et al
1996).
• There was a similar pattern among States and Territories for women in the target age group,
20-69 years. The Northern Territory mortality rate (8.7 per 100,000 women) was again more
than double that of the next highest State, Tasmania (4.2 per 100,000 women), and South
Australia (2.1 per 100,000 women) and Victoria (2.3 per 100,000 women) had the lowest rates
of mortality from cervical cancer (Table 25, page 71).
Refer to Tables 23 and 25 (pages 69 and 71).
Notes
1. The age-standardised rates were averaged over 4 years to smooth annual variations that may occur
in the smaller States and Territories.
2. Deaths derived from place of usual residence and not place of death.
3. Rates are expressed per 100,000 women and age standardised to the Australian 1991 population.
4. Bars on graphs represent 95% confidence intervals.
Source: AIHW Mortality Database.
Figure 17: Age-standardised cervical cancer mortality rates by women aged 20-69
years, by States and Territories, 1992-1995 and 1996-1999
NSW Vic Qld WA SA Tas ACT NT Australia
Rate 1992-1995 3.9 3.2 3.6 4.2 2.3 5.9 2.9 10.4 3.6
95% CI 3.4-4.3 2.8-3.7 3.0-4.2 3.3-5.1 1.6-3.0 4.1-8.0 1.2-4.8 4.6-16.7 3.4-3.9
Rate 1996-1999 2.9 2.3 2.9 3.2 2.1 4.2 3.8 8.7 2.8
95% CI 2.6-3.2 2.0-2.6 2.5-3.4 2.5-3.8 1.5-2.6 2.9-5.7 2.1-5.6 4.5-13.5 2.6-3.0
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Indicator 9: Mortality by location
Mortality rates from cervical cancer per 100,000 estimated resident female population in a
3-year period by location and 5-year age groups (20-24, 25-29, 30-34, 35-39, 40-44, 45-49,
50-54, 55-59, 60-64, 65-69, 70-74, 75-79, 80-84, 85+) and for the target age group (20-69
years, age-standardised).
The graph and table below refer to the data for the target age group only. For detailed data
refer to Table 27 (page 73).
• In the 3-year period 1997-1999 there were 551 deaths from cervical cancer in metropolitan
locations (70% of all cervical cancer deaths), 208 deaths (26% of all cervical cancer deaths) in
rural locations and 30 deaths (4% of all cervical cancer deaths) in remote locations (Table 26,
page 72).
• The age-standardised cervical cancer mortality rate for women in the target age group
20-69 years was highest in remote locations (4.7 per 100,000 women) in the period
1997-1999. During the same period the rate for cervical cancer mortality in both
metropolitan and rural locations were 2.4 per 100,000 women (Table 27, page 73).
Notes
1. The age-standardised rates are presented as 3-year rolling blocks of data.
2. Deaths derived from place of usual residence and not place of death.
3. Rates are expressed per 100,000 women and age standardised to the Australian 1991 population.
4. Bars on graphs represent 95% confidence intervals.
Source: AIHW Mortality Database.
Figure 18: Age-standardised cervical cancer mortality rates by women aged 20-69
years, by location, 1996-1998 and 1997-1999
Metropolitan Rural Remote
1996-1998 1997-1999 1996-1998 1997-1999 1996-1998 1997-1999
Rate 2.6 2.4 3.1 2.4 5.5 4.7
95% CI 2.4-2.9 2.2-2.7 2.5-3.6 2.0-2.9 3.3-7.9 2.8-7.0
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• The age-standardised cervical cancer mortality rate declined for all locations between the
periods 1996-1998 and 1997-1999, for women in the target age group 20-69 years. The overall
decline in the target age group was 8% in metropolitan locations, 23% in rural locations, and
15% in remote locations (Table 27, page 73).
• The higher mortality rate in remote location reflects to a large extent the relatively high
proportion of Indigenous people in remote areas, and the higher mortality rates among
Indigenous women (see Indicator 10).
Age-specific features
(Tables 26 and 27, pages 72 and 73)
• Between the periods 1996-1998 and 1997-1999, mortality from cervical cancer has declined in
nearly all age groups in metropolitan and rural areas. Numbers in remote areas are small and
trends are difficult to assess.
• In all geographical locations, the age-specific mortality rates increased with increasing age.
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Indicator 10: Indigenous mortality
Mortality rates from cervical cancer per 100,000 estimated resident female population in a
3-year period by Indigenous status and 5-year age groups (20-24, 25-29, 30-34, 35-39, 40-44,
45-49, 50-54, 55-59, 60-64, 65-69, 70-74, 75-79, 80-84, 85+) and for the target age group
(20-69 years, age-standardised).
The graph and table below refer to the data for the target age group only. For detailed data
refer to Table 29 (page 75).
• Due to the difficulties of Indigenous identification in health data collections, only mortality
data from Western Australia, South Australia and the Northern Territory are of sufficient
quality to be publishable. Therefore all cervical cancer mortality data for both Indigenous
women and non-Indigenous women used in this analysis are confined to these States and
Territory.
Notes
1. The age-standardised rates are presented as 3-year rolling blocks of data.
2. Deaths derived from place of usual residence and not place of death.
3. Rates are expressed per 100,000 women and age standardised to the Australian 1991 population.
4. Only Western Australia, South Australia and the Northern Territory have Indigenous death
registration data considered to be of a publishable standard.
5. Bars on graphs represent 95% confidence intervals.
Source: AIHW Mortality Database.
Figure 19: Age-standardised cervical cancer mortality rates by women aged 20-69
years, by Indigenous status, 1993-1995, 1996-1998 and 1997-1999
Indigenous Non-Indigenous
1993-1995 1996-1998 1997-1999 1993-1995 1996-1998 1997-1999
AS rate (A) 24.1 19.0 15.8 3.4 2.3 2.2
95% CI 11.9-37.6 9.0-31.2 6.8-24.6 2.8-4.1 1.8-2.9 1.7-2.7
40
• In the 1997-1999 period there were 18 deaths attributable to cervical cancer among Indigenous
women, an age-standardised rate of 29.0 per 100,000 women. This is over nine times the
mortality rate for non-Indigenous women (3.2 per 100,000 women) (Tables 28 and 29, pages
74 and 75).
• The age-standardised mortality rate for Indigenous women in the target age group 20-69 years
was 15.8 per 100,000 women for the period 1997-1999. The comparative figure for non-
Indigenous women was 2.2 per 100,000 women (Table 29, page 75).
• Between the two periods 1996-1998 and 1997-1999, the Indigenous cervical cancer mortality
rate among women in the target age group 20-69 years declined from 19 to 15.8 deaths per
100,000 women. When the mortality rate for the period 1993-1995 was included for
comparison, the Indigenous mortality rate for the target age group still shows a decline.
However, these rates are based on relatively small numbers of cases and may be subject to
large variability. This is reflected in the wide confidence intervals associated with the mortality
rates. Despite the relatively large size of the apparent decline in the rate, it is still within the
range of variation that would be expected due to chance, that is, it is not statistically significant
(Table 29, page 75).
Age-specific features
(Tables 28 and 29, pages 74 and 75)
• The numbers of deaths among Indigenous women in Western Australia, South Australia and
the Northern Territory are very small in most age groups and care is needed in interpreting the
rates.
• Mortality rates generally increased with increasing age in both Indigenous and non-Indigenous
women.
• Compared with non-Indigenous women, Indigenous women experienced high rates of
mortality at almost every age group.
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Indicator 1: Participation
Table 1a: Number of women participating in the National Cervical Screening Program by age,
States and Territories, 1997-1998
Age group NSW Vic WA(a) SA(b) Tas ACT(a) NT Australia
20-24 106,771 82,031 36,422 27,668 9,989 7,042 4,880 274,803
25-29 152,260 122,571 47,752 36,982 11,899 8,772 6,228 386,464
30-34 154,446 126,446 48,703 38,060 11,989 8,552 5,441 393,637
35-39 154,060 127,261 49,431 39,175 12,698 8,407 4,846 395,878
40-44 130,315 110,367 42,817 34,069 10,682 7,587 3,799 339,636
45-49 109,283 95,905 35,005 29,617 9,051 7,018 3,091 288,970
50-54 84,773 76,368 25,537 23,309 6,896 5,257 1,898 224,038
55-59 56,631 52,128 16,903 15,820 4,701 3,101 1,069 150,353
60-64 41,976 39,569 12,735 12,639 3,582 2,001 535 113,037
65-69 31,116 31,903 9,323 9,972 2,706 1,363 305 86,688
70-74 13,371 15,051 3,590 7,547 864 535 117 41,075
75-79 5,154 5,357 1,274 n.a. 319 195 52 12,351
80-84 1,562 1,721 389 n.a. 106 51 15 3,844
85+ 564 660 38 n.a. 35 15 8 1,320
Not stated 9,080 n.a. n.a. 389 4 40 43 9,556
All ages 1,051,362 887,338 329,919 275,247 85,521 59,936 32,327 2,721,650
Ages 20-69
years 1,021,631 864,549 324,628 267,311 84,193 59,100 32,092 2,653,504
(a) The WA and ACT registers only include women with valid WA and ACT addresses respectively.
(b) South Australia has grouped all women aged 70 years or more, and for the purposes of this table they appear in
the 70-74 age group.
Notes
1. These numbers may be overestimated because of double counting of some women between some States. This
may be the result of difficulty in identifying State of residence for women in border areas, tests inadvertently
transferred to interstate registers and inclusion of women resident overseas.
2. The Queensland Health Pap Smear Register began in February 1999, therefore no data are available for this
report.
Source: AIHW analysis of State and Territory Cervical Cytology Registry data.
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Table 1b: Proportion of women participating in the National Cervical Screening Program by
age, States and Territories, 1997-1998
Age group NSW Vic WA(a) SA(b) Tas ACT(a) NT Australia
(Per cent)
20-24 48.2 48.8 54.5 55.8 65.3 52.5 60.6 50.6
25-29 62.6 66.4 68.1 69.4 72.4 66.5 66.0 65.5
30-34 65.7 71.5 71.3 71.6 72.3 70.2 65.8 69.0
35-39 66.6 74.9 73.2 72.5 72.7 70.8 67.1 70.7
40-44 65.4 74.6 71.4 72.0 70.2 71.7 64.3 69.8
45-49 64.3 75.6 69.6 71.0 69.8 72.8 68.1 69.4
50-54 66.1 80.7 72.0 74.0 70.9 79.4 64.7 72.5
55-59 56.6 70.8 62.3 65.0 60.4 71.3 60.7 62.9
60-64 48.3 61.6 57.0 59.0 53.4 63.2 46.8 54.9
65-69 36.4 51.3 45.1 46.6 41.5 50.2 39.4 43.4
Ages 20-84(c)
Crude rate 55.9 63.3 62.3 61.7 61.7 64.4 63.2 59.9
AS rate 54.9 63.1 60.7 62.1 61.5 62.1 57.8 59.2
95% CI 54.8-55.0 63.0-63.2 60.5-60.9 61.9-62.4 61.1-61.9 61.6-62.6 57.1-58.5 59.1-59.2
Target age 20-69 years
Crude rate 60.1 68.1 66.4 67.2 67.5 67.4 64.1 64.4
AS rate 59.4 67.8 65.7 66.7 66.9 67.0 62.0 63.9
95% CI 59.3-59.5 67.7-68.0 65.4-65.9 66.5-67.0 66.5-67.3 66.5-67.6 61.3-62.7 63.8-63.9
(a) The WA and ACT registers only include women with valid WA and ACT addresses, respectively.
(b) South Australia has grouped all women aged 70 years or more, and for the purposes of this table they appear in
the 70-74 age group.
(c) Crude and age-standardised rates exclude women screened in the 85+ age group because hysterectomy fractions
are not available for this age group.
(d) Age-standardised rates exclude cases for which ages are not stated.
Notes
1. These numbers may be overestimated because of double counting of some women between some States. This
may be the result of difficulty in identifying State of residence for women in border areas, tests inadvertently
transferred to interstate registers and inclusion of women resident overseas.
2. The Queensland Health Pap Smear Register began in February 1999, therefore no data are available for this
report.
3. Rates are standardised to the 1991 Australian total population.
Source: AIHW analysis of State and Territory Cervical Cytology Registry data.
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Table 2a: Number of women participating in the National Cervical Screening Program by age,
States and Territories, 1998-1999
Age group NSW Vic WA(a) SA(b) Tas ACT(a) NT Australia
20-24 105,105 89,660 36,858 27,282 9,466 6,803 4,700 279,874
25-29 152,831 128,002 47,821 36,257 11,298 8,589 6,208 391,006
30-34 154,747 129,131 48,370 37,393 11,482 8,293 5,586 395,002
35-39 158,287 129,303 49,374 39,258 12,479 8,350 4,963 402,014
40-44 135,791 112,158 43,327 35,207 10,685 7,563 4,050 348,781
45-49 114,246 96,199 35,585 30,489 9,030 7,019 3,321 295,889
50-54 91,705 77,518 26,608 24,842 7,222 5,785 2,217 235,897
55-59 61,286 52,870 17,411 16,762 4,845 3,404 1,273 157,851
60-64 45,955 41,426 13,272 13,327 3,689 2,177 641 120,487
65-69 32,950 32,337 9,512 10,243 2,753 1,413 355 89,563
70-74 14,341 12,107 3,656 7,043 842 583 147 38,719
75-79 5,440 4,559 1,311 n.a. 334 198 72 11,914
80-84 1,517 1,437 382 n.a. 98 45 15 3,494
85+ 534 618 49 n.a. 36 22 8 1,267
Not stated 5,485 n.a. n.a. 31 7 15 28 5,566
All ages 1,080,220 907,325 333,536 278,134 84,266 60,259 33,584 2,777,324
Ages 20-69
years 1,052,903 888,604 328,138 271,060 82,949 59,396 33,314 2,716,364
(a) The WA and ACT registers only include women with valid WA and ACT addresses, respectively.
(b) South Australia has grouped women aged 70 years or more, and for the purpose of this table they appear in the
70-74 age group.
Notes
1. These numbers may be overestimated because of double counting of some women between some States. This
may be the result of difficulty in identifying State of residence for women in border areas, tests inadvertently
transferred to interstate registers and inclusion of women resident overseas.
2. The Queensland Health Pap Smear Register began in February 1999, therefore no data are available for this
report.
Source: AIHW analysis of State and Territory Cervical Cytology Registry data.
45
Table 2b: Proportion of women participation in the National Cervical Screening Program by
age, States and Territories, 1998-1999
Age group NSW Vic WA(a) SA(b) Tas ACT(a) NT Australia
(Per cent)
20-24 48.1 53.6 54.7 55.9 63.7 51.9 59.7 52.0
25-29 62.3 69.2 67.6 68.9 70.1 65.4 65.8 66.0
30-34 66.6 72.9 71.2 71.5 71.6 69.3 66.9 69.7
35-39 67.9 75.5 72.3 72.9 72.4 71.5 67.7 71.4
40-44 67.2 74.9 71.2 74.0 70.0 71.8 68.0 70.9
45-49 66.1 74.7 68.8 72.2 68.8 73.1 71.1 69.9
50-54 68.5 78.0 70.7 75.4 71.1 82.4 70.6 72.8
55-59 59.2 69.6 61.9 66.9 60.7 74.3 67.0 63.9
60-64 52.0 63.6 57.5 61.2 54.1 66.1 53.8 57.4
65-69 39.1 52.2 45.7 48.5 42.3 51.7 44.9 45.2
Ages 20-84(c)
Crude rate 56.9 64.1 61.9 62.2 60.9 64.2 64.9 60.6
AS rate 56.2 63.8 60.4 62.8 60.9 62.6 60.4 60.0
95% CI 56.1-56.3 63.6-63.9 60.2-60.6 62.5-63.0 60.5-61.4 62.1-63.1 59.7-61.2 59.9-60.0
Age 20-69 years
Crude rate 61.4 69.3 66.1 68.1 66.8 67.8 65.8 65.4
AS rate 60.8 68.9 65.4 67.6 66.3 67.6 64.5 64.8
95% CI 60.7-60.9 68.8-69.0 65.1-65.6 67.3-67.8 65.8-66.7 67.0-68.1 63.7-65.3 64.8-64.9
(a) The WA and ACT registers only include women with valid WA and ACT addresses, respectively.
(b) South Australia has grouped women aged 70 years or more, and for the purpose of this table they appear in the
70-74 age group.
(c) Crude and age-standardised rates exclude women screened in the 85+ age group because hysterectomy fractions
are not available for this age group.
(d) Age-standardised rates exclude cases for which ages are not stated.
Notes
1. These numbers may be overestimated because of double counting of some women between some States. This
may be the result of difficulty in identifying State of residence for women in border areas, tests inadvertently
transferred to interstate registers and inclusion of women resident overseas.
2. The Queensland Health Pap Smear Register began in February 1999, therefore no data are available for this
report.
3. Rates are standardised to the 1991 Australian total population.
Source: AIHW analysis of State and Territory Cervical Cytology Registry data.
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Table 4: Percentage of women with repeat screenings in the 24 months following a negative
smear in February 1998 by States and Territories, and Australia, 1997-1998, and in the
24 months following a negative Pap smear in February 1997, Australia, 1997-1998
Indicator 2: Early rescreening
Table 3: Number of women with repeat screenings in the 24 months following a negative Pap
smear in February 1998 by States and Territories, and Australia, 1998-1999, and in the
24 months following a negative Pap smear in February 1997, Australia, 1997-1998
No. of tests NSW Vic WA(a) SA Tas ACT(a) NT Australia
1998-1999
Australia
1997-1998
Number of women
0 30,159 25,711 8,853 7,992 2,300 2,600 1,078 78,693 76,560
1 18,232 17,229 5,913 4,283 1,259 713 459 48,088 53,456
2 3,408 3,820 1,195 724 236 102 87 9,572 10,922
3 492 726 134 158 25 12 21 1,568 2,080
4 109 244 20 30 6 0 3 412 508
5 or more 20 121 6 9 0 0 1 157 196
(a) The WA and ACT registers only include women with valid WA and ACT addresses, respectively.
Notes
1. These numbers may be overestimated because of double counting of some women between some States. This
may be the result of difficulty in identifying State of residence for women in border areas, tests inadvertently
transferred to interstate registers and inclusion of women resident overseas.
2. The Queensland Health Pap Smear Register began in February 1999, therefore no data are available for this
report.
Source: State and Territory Cervical Cytology Registry data.
No. of tests NSW Vic WA(a) SA Tas ACT(a) NT Australia
1998-1999
Australia
1997-1998
Per cent of women
0 57.5 53.7 54.9 60.6 60.1 75.9 65.4 56.8 53.3
1 34.8 36.0 36.7 32.5 32.9 20.8 27.8 34.7 37.2
2 6.5 8.0 7.4 5.5 6.2 3.0 5.3 6.9 7.6
3 0.9 1.5 0.8 1.2 0.7 0.4 1.3 1.1 1.4
4 0.2 0.5 0.1 0.2 0.2 0.0 0.2 0.3 0.4
5 or more 0.0 0.3 0.0 0.1 0.0 0.0 0.1 0.1 0.1
(a) The WA and ACT registers only include women with valid WA and ACT addresses, respectively.
Notes
1. These numbers may be overestimated because of double counting of some women between some States. This
may be the result of difficulty in identifying State of residence for women in border areas, tests inadvertently
transferred to interstate registers and inclusion of women resident overseas.
2. The Queensland Health Pap Smear Register began in February 1999, therefore no data are available for this
report.
Source: State and Territory Cervical Cytology Registry data.
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Table 5b: Number of low- and high-grade abnormalities on histology for women aged
20-69 years, by States and Territories, 1999
Indicator 3: Low-grade abnormality detection
Table 5a: Number of low- and high-grade abnormalities on histology for women aged
20-69 years, by States and Territories, 1998
Abnormalities NSW Vic WA SA Tas NT Australia
Low-grade 5,799 3,329 2,090 2,179 756 258 14,411
High-grade 3,960 2,994 1,414 1,505 534 298 10,701
Ratio 1.46 1.11 1.48 1.45 1.42 0.87 1.35
As a percentage of all screens in 1998
Low-grade 0.9 0.6 1.1 1.4 1.6 1.4 0.9
High-grade 0.6 0.6 0.7 1.0 1.1 1.6 0.7
Notes
1. These numbers may be overestimated because of double counting of some women between some States. This
may be the result of difficulty in identifying State of residence for women in border areas, tests inadvertently
transferred to interstate registers and inclusion of women resident overseas.
2. The Queensland Health Pap Smear Register began in February 1999, therefore no data are available for this
report.
3. The ACT did not collect histology details during this period; therefore no data are available for this indicator.
Source: State and Territory Cervical Cytology Registry data.
Abnormalities NSW Vic WA SA Tas ACT NT Australia
Low-grade 6,207 4,197 2,563 1,767 640 221 158 15,753
High-grade 4,523 3,546 1,509 1,237 470 178 179 11,642
Ratio 1.37 1.18 1.70 1.43 1.36 1.24 0.88 1.35
As a percentage of all screens in 1999
Low-grade 1.0 0.8 1.3 1.2 1.4 1.8 0.9 1.0
High-grade 0.8 0.7 0.8 0.8 1.0 1.4 1.0 0.8
Notes
1. These numbers may be overestimated because of double counting of some women between some States. This
may be the result of difficulty in identifying State of residence for women in border areas, tests inadvertently
transferred to interstate registers and inclusion of women resident overseas.
2. The Queensland Health Pap Smear Register began in February 1999, therefore no data are available for this
report.
Source: State and Territory Cervical Cytology Registry data.
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Indicator 4: High-grade abnormality detection
Table 6a: Rate of histologically confirmed high-grade abnormalities per 1,000 women
screened, by States and Territories, 1998
Age group NSW Vic WA SA(a) Tas NT Australia
20-24 13.9 11.9 13.9 18.9 22.9 24.6 14.3
25-29 13.0 12.2 13.9 18.9 19.9 26.5 13.9
30-34 8.1 7.7 9.3 11.6 15.8 18.3 8.8
35-39 5.7 5.6 6.1 8.3 11.5 13.5 6.3
40-44 3.6 3.5 4.7 6.6 6.3 8.4 4.1
45-49 2.4 1.9 2.4 4.9 4.0 4.5 2.6
50-54 1.9 1.4 1.6 3.7 1.7 7.3 1.9
55-59 1.5 1.2 1.9 3.2 1.5 6.5 1.6
60-64 1.5 1.6 1.5 3.2 2.5 3.2 1.7
65-69 0.9 0.8 1.1 2.5 0.0 0.0 1.0
70-74 2.5 0.8 n.a. 6.9 0.0 0.0 2.9
75-79 2.5 2.2 n.a. n.a. 0.0 0.0 3.4
80-84 7.5 3.1 n.a. n.a. 19.6 0.0 6.0
85+ 6.8 3.9 n.a. n.a. 0.0 0.0 4.8
All ages 6.4 5.6 7.2 9.5 10.9 16.0 6.8
Ages 20-69
years 6.4 5.7 7.1 9.6 11.0 16.1 6.7
(a) South Australia has grouped all women aged 70 years or more, and for the purposes of this table they
appear in the 70-74 age group.
Notes
1. These numbers may be overestimated because of double counting of some women between some States.
This may be the result of difficulty in identifying State of residence for women in border areas, tests
inadvertently transferred to interstate registers and inclusion of women resident overseas.
2. The Queensland Health Pap Smear Register began in February 1999, therefore no data are available for
this report.
3. The ACT did not collect histology details during this period; therefore no data are available for this
indicator.
Source: State and Territory Cervical Cytology Registry data.
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Table 6b: Rate of histologically confirmed high-grade abnormalities per 1,000 women
screened, by States and Territories, 1999
Age group NSW Vic WA SA(a) Tas ACT NT Australia
20-24 18.3 15.9 15.5 16.8 23.1 8.5 13.4 16.8
25-29 14.8 14.1 17.4 15.4 21.0 10.1 15.8 15.0
30-34 9.9 9.2 10.6 11.8 12.1 10.1 11.1 10.0
35-39 6.7 6.2 6.7 7.0 8.4 8.3 9.6 6.7
40-44 4.3 3.8 4.4 6.5 5.8 5.5 4.0 4.4
45-49 3.0 2.7 3.1 5.0 4.6 4.4 4.8 3.2
50-54 2.2 1.4 1.5 2.9 3.0 1.5 3.9 2.0
55-59 1.4 1.5 1.6 2.6 1.4 3.1 7.9 1.7
60-64 1.3 1.7 1.6 1.8 1.9 3.4 0.0 1.6
65-69 2.2 1.3 2.3 2.4 1.3 6.8 9.3 2.0
70-74 1.7 2.4 0.9 6.8 4.4 10.9 12.8 2.9
75-79 4.5 1.5 5.7 n.a. 0.0 48.1 0.0 4.1
80-84 2.4 2.5 3.8 n.a. 20.4 0.0 0.0 3.0
85+ 0.0 2.9 44.4 n.a. 0.0 0.0 0.0 4.4
All ages 7.4 6.8 7.8 8.3 9.9 7.0 9.7 7.5
Ages 20-69
years 7.6 6.9 7.9 8.4 10.0 6.8 9.7 7.5
(a) South Australia has grouped all women aged 70 years or more, and for the purpose of this table they appear in
the 70-74 age group.
Notes
1. These numbers may be overestimated because of double counting of some women between some States. This
may be the result of difficulty in identifying State of residence for women in border areas, tests inadvertently
transferred to interstate registers and inclusion of women resident overseas.
2. The Queensland Health Pap Smear Register began in February 1999, therefore no data are available for this
report.
Source: State and Territory Cervical Cytology Registry data.
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Table 7a: Number of histologically confirmed high-grade abnormalities by age, by States and
Territories, 1998
Age group NSW Vic WA SA(a) Tas NT Australia
20-24 847 566 309 305 127 66 2,220
25-29 1,180 895 408 411 137 95 3,126
30-34 748 591 276 259 109 58 2,041
35-39 531 437 184 192 85 39 1,468
40-44 284 233 124 134 39 19 833
45-49 163 116 52 87 21 8 447
50-54 101 65 25 51 7 8 257
55-59 51 38 19 29 4 4 145
60-64 37 38 11 23 5 1 115
65-69 17 15 6 14 0 0 52
70-74 19 8 6 29 0 0 62
75-79 7 7 7 n.a. 0 0 21
80-84 6 3 1 n.a. 1 0 11
85+ 2 2 0 n.a. 0 0 4
Age not
stated 3 n.a. n.a. 1 0 0 4
All ages 3,996 3,014 1,428 1,535 535 298 10,806
Ages 20-69
years 3,960 2,994 1,414 1,505 534 298 10,704
(a) South Australia has grouped all women aged 70 years or more, and for the purposes of this table they appear in
the 70-74 age group.
Notes
1. These numbers may be overestimated because of double counting of some women between some States. This
may be the result of difficulty in identifying State of residence for women in border areas, tests inadvertently
transferred to interstate registers and inclusion of women resident overseas.
2. The Queensland Health Pap Smear Register began in February 1999, therefore no data are available for this
report.
Source: State and Territory Cervical Cytology Registry data.
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Table 7b: Number of histologically confirmed high-grade abnormalities by age, by States and
Territories, 1999
Age group NSW Vic WA SA(a) Tas ACT NT Australia
20-24 1,031 787 316 247 118 31 35 2,565
25-29 1,252 1,031 466 300 131 49 54 3,283
30-34 859 690 290 240 79 46 34 2,238
35-39 599 461 188 150 59 38 25 1,520
40-44 332 249 114 125 36 23 9 888
45-49 201 152 67 84 24 17 9 554
50-54 122 64 25 41 13 5 5 275
55-59 51 48 17 24 4 6 6 156
60-64 35 40 13 13 4 4 0 109
65-69 41 22 13 13 2 5 2 98
70-74 14 16 2 23 2 3 1 61
75-79 14 4 5 n.a. 0 5 0 28
80-84 2 2 1 n.a. 1 0 0 6
85+ 0 1 2 n.a. 0 0 0 3
Age not
stated 5 0 0 0 0 0 0 5
All ages 4,558 3,569 1,519 1,260 473 232 180 11,789
Ages 20-69
years 4,523 3,546 1,509 1,237 470 224 179 11,686
(a) South Australia has grouped all women aged 70 years or more, and for the purpose of this table they appear in
the 70-74 age group
Notes
1. These numbers may be overestimated because of double counting of some women between some States. This
may be the result of difficulty in identifying State of residence for women in border areas, tests inadvertently
transferred to interstate registers and inclusion of women resident overseas.
2. The Queensland Health Pap Smear Register began in February 1999, therefore no data are available for this
report.
Source: State and Territory Cervical Cytology Registry data.
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Table 8a: Number of women screened by age, by States and Territories, 1998
Age group NSW Vic WA SA(a) Tas NT Australia
20-24 60,919 47,286 22,267 16,122 5,532 2,678 154,804
25-29 90,720 73,379 29,342 21,785 6,883 3,584 225,693
30-34 92,053 76,937 29,693 22,260 6,911 3,170 231,024
35-39 93,293 77,383 30,288 23,111 7,387 2,896 234,358
40-44 79,402 67,374 26,259 20,351 6,177 2,249 201,812
45-49 66,812 58,146 21,676 17,464 5,207 1,783 171,088
50-54 52,675 46,514 15,753 13,857 4,073 1,092 133,964
55-59 34,574 31,584 10,123 9,087 2,723 615 88,706
60-64 25,243 23,974 7,609 7,138 2,000 308 66,272
65-69 17,970 19,257 5,453 5,526 1,476 153 49,835
70-74 7,685 9,235 n.a. 4,161 503 73 21,657
75-79 2,841 3,170 n.a. n.a. 183 32 6,226
80-84 805 979 n.a. n.a. 51 8 1,843
85+ 293 518 n.a. n.a. 16 6 833
Age not
stated 4,335 n.a. n.a. 132 3 22 4,492
All ages 629,620 535,736 198,463 160,994 49,125 18,669 1,592,607
Ages 20-69
years 613,661 521,834 198,463 156,701 48,369 18,528 1,557,556
(a) South Australia has grouped all women aged 70 years or more, and for the purposes of this table they appear in
the 70-74 age group.
Notes
1. These numbers may be overestimated because of double counting of some women between some States. This
may be the result of difficulty in identifying State of residence for women in border areas, tests inadvertently
transferred to interstate registers and inclusion of women resident overseas.
2. The Queensland Health Pap Smear Register began in February 1999, therefore no data are available for this
report.
Source: State and Territory Cervical Cytology Registry data.
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Table 8b: Number of women screened by age, by States and Territories, 1999
Age group NSW Vic WA SA(a) Tas ACT NT Australia
20-24 56,207 49,642 20,430 14,682 5,112 3,647 2,617 152,337
25-29 84,768 72,923 26,751 19,534 6,247 4,856 3,420 218,499
30-34 87,185 74,662 27,357 20,319 6,536 4,573 3,068 223,700
35-39 89,864 74,680 28,256 21,299 7,065 4,557 2,616 228,337
40-44 77,916 65,350 25,624 19,272 6,199 4,184 2,225 200,770
45-49 66,105 56,250 21,453 16,760 5,225 3,875 1,860 171,528
50-54 54,472 46,336 16,802 13,938 4,302 3,299 1,289 140,438
55-59 36,266 31,374 10,801 9,400 2,854 1,922 757 93,374
60-64 27,057 23,708 8,133 7,351 2,113 1,164 361 69,887
65-69 18,896 17,423 5,611 5,476 1,582 738 215 49,941
70-74 8,061 6,696 2,276 3,361 451 276 78 21,199
75-79 3,103 2,600 872 n.a. 173 104 46 6,898
80-84 832 811 260 n.a. 49 19 7 1,978
85+ 263 344 45 n.a. 21 10 2 685
Age not
stated 2,406 0 0 11 5 8 11 2,441
All ages 613,401 522,799 194,671 151,403 47,934 33,232 18,572 1,582,012
Ages 20-69
years 598,736 512,348 191,218 148,031 47,235 32,815 18,428 1,548,811
(a) South Australia has grouped all women aged 70 years or more, and for the purpose of this table they appear in
the 70-74 age group.
Notes
1. These numbers may be overestimated because of double counting of some women between some States. This
may be the result of difficulty in identifying State of residence for women in border areas, tests inadvertently
transferred to interstate registers and inclusion of women resident overseas.
2. The Queensland Health Pap Smear Register began in February 1999, therefore no data are available for this
report.
Source: State and Territory Cervical Cytology Registry data.
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Table 9a: Age-standardised high-grade abnormality rate on histology per 1,000 women
screened aged 20-69 years, States and Territories, 1998
NSW Vic WA SA Tas ACT NT Australia
All ages
AS rate 6.0 5.4 6.0 8.8 9.8 n.a. 11.9 6.4
95% CI 5.7-6.2 5.1-5.6 5.7-6.4 8.4-9.3 8.8-11.0 n.a. 10.5-13.4 6.3-6.6
Target age 20-69
AS rate 6.3 5.8 6.7 9.5 10.5 n.a. 13.3 6.7
95% CI 6.1-6.5 5.5-6.0 6.4-7.1 9.0-10.1 9.7-11.4 n.a. 11.7-14.9 6.6-6.9
Notes
1. These numbers may be overestimated because of double counting of some women between some States. This
may be the result of difficulty in identifying State of residence for women in border areas, tests inadvertently
transferred to interstate registers and inclusion of women resident overseas.
2. The Queensland Health Pap Smear Register began in February 1999, therefore no data are available for this
report.
3. The ACT did not collect histology details during this period; therefore no data are available for this report.
4. Standardised to the 1991 Australian total population.
Source: AIHW analysis of State and Territory Cervical Cytology Registry data.
Table 9b: Age-standardised high-grade abnormality rate on histology per 1,000 women
screened aged 20-69 years, States and Territories, 1999
NSW Vic WA SA Tas ACT NT Australia
All ages
AS rate 7.1 6.4 7.8 7.9 9.5 6.5 8.4 7.1
95% CI 6.9-7.3 6.2-6.7 7.0-8.8 7.4-8.3 8.4-10.7 5.5-7.5 6.8-10.2 7.0-7.3
Target age 20-69
AS rate 7.7 6.9 7.7 8.5 9.9 6.8 8.7 7.6
95% CI 7.4-7.9 6.7-7.2 7.4-8.2 8.0-9.0 9.0-10.9 5.8-7.7 7.4-10.2 7.4-7.7
Notes
1. These numbers may be overestimated because of double counting of some women between some States. This
may be the result of difficulty in identifying State of residence for women in border areas, tests inadvertently
transferred to interstate registers and inclusion of women resident overseas.
2. The Queensland Health Pap Smear Register began in February 1999, therefore no data are available for this
report.
3. Standardised to the 1991 Australian total population.
Source: AIHW analysis of State and Territory Cervical Cytology Registry data.
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Indicator 5: Incidence of micro-invasive cervical cancer
Table 10: New cases of micro-invasive cervical cancer by age, Australia, 1987-1998
Age group 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998
0-4 0 0 0 0 0 0 0 0 0 0 0 0
5-9 0 0 0 0 0 0 0 0 0 0 0 0
10-14 0 0 0 0 0 0 0 0 0 0 0 0
15-19 0 0 0 0 1 0 0 0 0 0 0 0
20-24 3 4 1 4 0 5 1 7 1 6 2 3
25-29 8 13 12 15 14 13 7 17 17 18 10 17
30-34 18 20 26 31 31 32 31 32 41 18 27 18
35-39 25 13 10 24 38 23 26 31 29 35 22 24
40-44 14 12 17 22 32 24 16 25 29 23 21 20
45-49 10 9 5 18 10 12 15 27 22 11 11 12
50-54 3 6 4 4 11 12 17 9 12 11 8 12
55-59 4 5 5 8 6 12 5 5 8 7 7 3
60-64 3 2 6 8 7 7 6 10 10 6 5 5
65-69 1 2 2 6 7 9 10 6 7 10 2 2
70-74 0 0 0 2 4 2 4 6 5 3 4 3
75-79 1 1 1 3 3 2 1 3 5 2 2 2
80-84 0 0 1 0 2 0 0 0 1 1 0 1
85+ 0 0 0 0 0 0 1 2 1 1 0 0
All ages 90 87 90 145 166 153 140 180 188 152 121 122
Ages 20-69
years 89 86 88 140 156 149 134 169 176 145 115 116
Source: National Cancer Statistics Clearing House (AIHW).
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Table 11: Age-specific and age-standardised rates of micro-invasive cervical cancer by age,
Australia, 1987-1998
Age group 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998
0-4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5-9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
10-14 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15-19 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0
20-24 0.5 0.6 0.2 0.6 0.0 0.7 0.1 1.0 0.1 0.9 0.3 0.5
25-29 1.2 1.9 1.7 2.1 2.0 1.9 1.0 2.5 2.5 2.5 1.4 2.3
30-34 2.8 3.0 3.8 4.5 4.4 4.4 4.2 4.4 5.6 2.5 3.8 2.5
35-39 4.0 2.0 1.5 3.7 5.7 3.4 3.8 4.4 4.1 4.8 3.0 3.2
40-44 2.6 2.1 2.9 3.6 5.0 3.7 2.5 3.8 4.3 3.4 3.0 2.8
45-49 2.4 2.1 1.1 3.8 2.0 2.2 2.6 4.5 3.6 1.7 1.7 1.8
50-54 0.8 1.6 1.0 1.0 2.7 2.8 3.9 2.0 2.5 2.2 1.5 2.1
55-59 1.1 1.4 1.4 2.2 1.7 3.3 1.3 1.3 2.0 1.7 1.7 0.7
60-64 0.8 0.5 1.6 2.2 1.9 1.9 1.7 2.8 2.8 1.7 1.4 1.4
65-69 0.3 0.6 0.6 1.7 2.0 2.5 2.8 1.7 2.0 2.8 0.6 0.6
70-74 0.0 0.0 0.0 0.7 1.4 0.7 1.3 1.9 1.5 0.9 1.2 0.9
75-79 0.5 0.5 0.5 1.4 1.3 0.9 0.4 1.3 2.1 0.8 0.8 0.7
80-84 0.0 0.0 0.7 0.0 1.4 0.0 0.0 0.0 0.6 0.6 0.0 0.6
85+ 0.0 0.0 0.0 0.0 0.0 0.0 0.8 1.6 0.7 0.7 0.0 0.0
All ages
Crude rate 1.1 1.1 1.1 1.7 1.9 1.7 1.6 2.0 2.1 1.7 1.3 1.3
AS rate (A) 1.6 1.5 1.5 2.4 2.7 2.5 2.2 2.8 2.9 2.3 1.8 1.8
95% CI 1.3-2.0 1.2-1.9 1.2-1.9 2.1-2.9 2.3-3.1 2.1-2.9 1.9-2.6 2.4-3.2 2.5-3.3 1.9-2.7 1.5-2.1 1.5-2.1
AS rate (W) 1.6 1.6 1.5 2.4 2.6 2.5 2.2 2.8 2.8 2.3 1.8 1.8
95% CI 1.3-2.0 1.2-1.9 1.2-1.8 2.0-2.9 2.2-3.0 2.1-2.9 1.8-2.5 2.4-3.2 2.4-3.2 1.9-2.6 1.4-2.1 1.5-2.1
Age 20-69 years
Crude rate 1.8 1.7 1.7 2.6 2.9 2.7 2.4 3.0 3.1 2.5 2.0 2.0
AS rate (A) 1.8 1.7 1.7 2.6 2.9 2.7 2.4 3.0 3.1 2.5 2.0 1.9
95% CI 1.5-2.2 1.4-2.1 1.4-2.0 2.2-3.1 2.4-3.3 2.3-3.2 2.0-2.8 2.6-3.4 2.6-3.5 2.1-2.9 1.6-2.3 1.6-2.3
AS rate (W) 1.7 1.7 1.6 2.5 2.7 2.6 2.3 2.9 2.9 2.4 1.9 1.9
95% CI 1.4-2.1 1.3-2.0 1.3-1.9 2.1-3.0 2.3-3.1 2.2-3.1 1.9-2.7 2.5-3.3 2.5-3.4 2.0-2.8 1.5-2.2 1.5-2.2
Note: Rates are expressed per 100,000 women and age standardised to the Australian 1991 population (A) and the
World Standard Population (W).
Source: National Cancer Statistics Clearing House (AIHW).
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Indicator 6: Incidence of invasive squamous,
adenocarcinoma, adeno-squamous and other cervical
cancer
Table 12: New cases of cervical cancer by age, Australia, 1987-1998
Age group 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998
0-4 0 1 0 0 0 0 0 0 0 0 0 0
5-9 0 0 0 0 0 0 0 1 0 0 0 0
10-14 0 0 0 0 0 0 0 0 0 0 0 0
15-19 3 4 1 1 1 0 1 1 2 1 1 1
20-24 16 18 16 13 11 9 10 16 5 15 9 13
25-29 64 76 66 61 48 51 36 48 51 43 42 47
30-34 137 130 127 109 119 106 105 119 112 69 77 85
35-39 149 137 121 154 140 126 129 130 114 139 101 101
40-44 113 124 127 136 153 128 129 131 117 117 103 103
45-49 96 92 90 122 101 100 99 132 98 102 80 110
50-54 65 63 83 66 91 78 89 88 57 78 75 65
55-59 60 66 84 81 57 78 80 73 66 64 50 55
60-64 106 91 82 77 84 77 75 89 67 61 53 55
65-69 87 102 98 73 90 88 93 92 77 65 54 60
70-74 78 55 66 68 78 70 65 77 74 58 44 61
75-79 55 50 50 49 48 52 49 65 50 49 46 44
80-84 31 34 26 29 40 34 36 39 30 40 31 39
85+ 26 22 19 23 35 21 22 24 32 25 28 29
All ages 1,086 1,065 1,056 1,062 1,096 1,018 1,018 1,125 952 926 794 868
Ages 20-69
years 893 899 894 892 894 841 845 918 764 753 644 694
Note: The above table includes the incidence of micro-invasive and invasive cervical cancers.
Source: National Cancer Statistics Clearing House (AIHW).
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Table 13: Age-specific and age-standardised incidence rates of cervical cancer by age,
Australia, 1987-1998
Age group 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998
0-4 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5-9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0
10-14 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15-19 0.4 0.6 0.1 0.1 0.2 0.0 0.2 0.2 0.3 0.2 0.2 0.2
20-24 2.5 2.8 2.4 1.9 1.6 1.3 1.4 2.3 0.7 2.2 1.3 2.0
25-29 9.4 10.9 9.3 8.6 6.9 7.4 5.3 6.9 7.4 6.1 5.8 6.4
30-34 21.2 19.7 18.7 15.7 16.7 14.6 14.4 16.2 15.3 9.5 10.8 12.0
35-39 23.9 21.6 18.7 23.5 21.1 18.6 18.7 18.6 16.0 19.1 13.6 13.5
40-44 21.1 21.8 21.3 22.0 23.9 19.9 19.9 19.9 17.5 17.2 14.9 14.7
45-49 22.8 21.1 19.7 25.5 20.1 18.6 17.3 22.3 15.9 15.9 12.5 16.9
50-54 17.7 16.7 21.3 16.5 22.0 18.4 20.5 19.2 12.0 15.7 14.0 11.4
55-59 16.3 18.2 23.3 22.6 15.9 21.3 21.3 18.7 16.7 15.7 11.9 12.8
60-64 28.8 24.6 22.1 20.8 22.7 21.1 20.9 24.9 18.8 17.1 14.6 14.9
65-69 27.5 31.0 28.6 20.9 25.6 24.9 26.2 26.2 21.7 18.3 15.4 17.2
70-74 29.2 20.6 24.8 25.1 27.6 23.9 21.4 24.6 22.9 17.7 13.4 18.5
75-79 27.7 24.3 23.3 22.2 21.3 22.7 21.3 28.1 21.4 20.1 18.0 16.4
80-84 25.0 26.3 19.4 20.8 27.5 22.5 22.7 23.3 17.4 22.6 17.3 21.7
85+ 26.8 22.0 18.4 21.8 31.8 18.2 18.1 18.8 23.8 17.7 18.8 18.6
All ages
Crude rate 13.3 12.9 12.5 12.4 12.6 11.6 11.5 12.5 10.5 10.1 8.5 9.2
AS rate (A) 13.4 12.9 12.5 12.3 12.3 11.3 11.1 12.0 10.0 9.5 8.0 8.6
AS rate (W) 11.0 10.6 10.3 10.2 10.1 9.3 9.1 9.9 8.1 7.8 6.5 7.0
Ages 20-69 years
Crude rate 17.9 17.7 17.2 16.8 16.6 15.3 15.2 16.3 13.4 13.0 11.0 11.7
AS rate (A) 18.0 17.7 17.2 16.8 16.5 15.3 15.1 16.1 13.3 12.8 10.8 11.5
AS rate (W ) 17.5 17.2 16.8 16.5 16.1 14.9 14.7 15.8 12.9 12.5 10.5 11.2
Note: Rates are expressed per 100,000 women and age standardised to the Australian 1991 population (A) and the
World Standard Population (W).
Source: National Cancer Statistics Clearing House (AIHW).
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Table 14a: Number of new cases of cervical cancer by age, by States and Territories, for the
4-year period 1994-1997
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0-4 0 0 0 0 0 0 0 0 0
5-9 0 0 0 0 1 0 0 0 1
10-14 0 0 0 0 0 0 0 0 0
15-19 3 2 0 0 0 0 0 5
20-24 10 13 16 3 0 3 0 0 45
25-29 50 43 43 20 16 6 4 2 184
30-34 135 90 74 32 24 15 4 3 377
35-39 165 113 109 39 28 12 7 11 484
40-44 141 134 84 54 28 10 11 6 468
45-49 152 98 78 37 26 9 5 7 412
50-54 117 72 59 22 12 5 5 6 298
55-59 89 61 44 27 14 8 7 3 253
60-64 92 76 38 31 18 10 2 3 270
65-69 103 72 54 29 18 8 1 3 288
70-74 96 55 44 25 21 7 3 2 253
75-79 68 64 41 12 15 8 0 2 210
80-84 43 44 18 15 11 4 5 0 140
85+ 37 34 20 12 5 1 0 0 109
All ages 1,301 969 724 358 237 106 54 48 3,797
Ages 20-69
years 1,054 772 599 294 184 86 46 44 3,079
Source: National Cancer Statistics Clearing House (AIHW).
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Table 14b: Age-specific rates of cervical cancer by States and Territories, for the 4-year period
1994-1997
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0-4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5-9 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0
10-14 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15-19 0.4 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.2
20-24 1.1 1.9 3.1 1.1 0.0 4.5 0.0 0.0 1.6
25-29 5.3 6.0 8.5 7.4 7.5 9.0 7.8 5.6 6.6
30-34 13.7 12.3 14.3 11.4 10.5 20.6 7.8 9.0 13.0
35-39 17.0 15.7 21.1 13.7 12.1 15.9 13.5 36.6 16.8
40-44 15.6 19.9 17.4 20.0 12.8 14.3 21.8 22.9 17.4
45-49 18.2 15.7 17.2 15.4 12.6 14.0 10.5 32.5 16.5
50-54 17.5 14.6 16.6 12.1 7.4 9.7 15.1 40.8 15.2
55-59 16.0 14.8 15.7 18.3 10.3 18.4 30.3 33.2 15.7
60-64 18.2 20.4 15.7 24.5 14.4 25.5 11.4 49.4 18.8
65-69 20.4 19.6 22.8 24.4 13.9 21.0 6.4 70.6 20.4
70-74 20.7 16.3 20.6 24.1 17.0 19.6 21.3 69.0 19.5
75-79 19.7 25.9 25.5 15.7 16.3 29.2 0.0 107.9 21.9
80-84 17.4 24.2 15.9 25.9 16.4 20.2 80.1 0.0 20.1
85+ 19.1 22.9 22.5 25.6 9.3 6.8 0.0 0.0 19.7
All ages
Crude rate 10.5 10.5 11.0 10.3 8.0 11.1 8.8 14.1 10.4
AS rate (A) 9.8 9.8 10.7 10.1 7.3 10.6 9.0 20.3 9.8
95% CI 9.3-10.4 9.2-10.5 9.9-11.5 9.0-11.1 6.3-8.2 8.7-12.7 6.7-11.5 14.0-27.1 9.5-10.1
AS rate (W) 8.1 8.0 8.8 8.3 5.9 8.7 7.3 16.4 8.1
95% CI 7.6-8.6 7.5-8.5 8.1-9.5 7.3-9.1 5.1-6.7 7.1-10.3 5.4-9.3 11.5-21.3 7.8-8.3
Ages 20-69 years
Crude rate 13.5 13.3 14.6 13.4 9.9 14.6 11.5 20.6 13.4
AS rate (A) 13.2 13.1 14.5 13.5 9.6 14.4 11.6 25.3 13.2
95% CI 12.5-14.0 12.2-14.1 13.3-15.6 11.9-15.0 8.3-11.0 11.6-17.6 8.4-15.1 16.8-33.5 12.8-13.7
AS rate (W) 12.9 12.8 14.1 13.2 9.4 14.0 11.5 24.9 12.9
95% CI 12.2-13.7 11.9-13.7 12.9-15.2 11.6-14.6 8.0-10.7 11.3-17.0 8.3-14.9 16.7-32.9 12.5-13.4
Note: Rates are expressed per 100,000 women and age standardised to the Australian 1991 population (A) and the
World Standard Population (W).
Source: National Cancer Statistics Clearing House (AIHW).
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Table 15a: Number of new cases of cervical cancer by age, by States and Territories, for the
4-year period 1995-1998
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0-4 0 0 0 0 0 0 0 0 0
5-9 0 0 0 0 0 0 0 0 0
10-14 0 0 0 0 0 0 0 0 0
15-19 2 1 2 0 0 0 0 0 5
20-24 12 9 13 3 0 5 0 0 42
25-29 56 39 42 15 16 8 4 3 183
30-34 120 79 74 30 24 14 1 1 343
35-39 157 97 102 39 20 20 9 11 455
40-44 136 116 80 58 24 9 10 7 440
45-49 148 93 66 41 22 8 4 8 390
50-54 117 60 52 20 11 5 5 5 275
55-59 82 61 41 24 13 7 4 3 235
60-64 84 62 38 24 15 9 2 2 236
65-69 85 64 54 25 16 7 2 3 256
70-74 90 55 38 22 21 6 3 2 237
75-79 65 53 39 12 13 5 0 2 189
80-84 46 50 15 14 11 1 3 0 140
85+ 34 36 22 15 6 0 1 0 114
All ages 1,234 875 678 342 212 104 48 47 3,540
Ages 20-69
years 997 680 562 279 161 92 41 43 2,855
Source: National Cancer Statistics Clearing House (AIHW).
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Table 15b: Age-specific rates of cervical cancer by States and Territories, for the 4-year period
1995-1998
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0-4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5-9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
10-14 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15-19 0.2 0.2 0.4 0.0 0.0 0.0 0.0 0.0 0.2
20-24 1.3 1.3 2.5 1.1 0.0 7.8 0.0 0.0 1.5
25-29 5.9 5.3 8.0 5.5 7.5 12.1 7.6 8.1 6.4
30-34 12.3 10.9 14.3 10.7 10.8 19.9 2.0 3.0 11.9
35-39 15.9 13.3 19.2 13.5 8.6 26.3 17.4 35.8 15.5
40-44 14.8 17.0 16.1 21.0 10.9 12.7 20.0 26.0 16.0
45-49 17.4 14.6 14.2 16.5 10.5 12.3 8.2 35.9 15.3
50-54 16.6 11.5 13.6 10.3 6.4 9.3 14.0 31.5 13.2
55-59 14.4 14.5 14.0 15.7 9.3 15.7 16.5 31.1 14.2
60-64 16.6 16.5 15.4 18.6 12.0 22.9 11.1 31.3 16.3
65-69 16.9 17.5 22.7 20.9 12.6 18.4 12.7 68.2 18.2
70-74 19.2 16.1 17.5 20.9 17.0 16.9 21.0 66.1 18.1
75-79 18.1 20.6 23.2 15.0 13.5 17.7 0.0 102.9 18.9
80-84 18.2 27.1 12.8 23.9 16.2 4.9 45.8 0.0 19.8
85+ 16.7 23.2 23.4 30.3 10.6 0.0 21.0 0.0 19.6
All ages
Crude rate 9.8 9.4 10.1 9.7 7.1 10.8 7.8 13.5 9.6
AS rate (A) 9.1 8.7 9.8 9.3 6.4 10.7 7.9 18.8 9.0
95% CI 8.6-9.6 8.1-9.3 9.0-10.5 8.3-10.3 5.5-7.3 8.6-12.8 5.8-10.3 12.6-24.8 8.7-9.3
AS rate (W) 7.5 7.0 8.0 7.6 5.2 9.0 6.4 15.2 7.4
95% CI 7.1-8.0 6.5-7.5 7.4-8.6 6.8-8.4 4.5-5.9 7.2-10.8 4.6-8.4 10.6-19.5 7.1-7.6
Ages 20-69 years
Crude rate 12.7 11.6 13.4 12.5 8.6 15.6 10.2 19.6 12.3
AS rate (A) 12.3 11.4 13.3 12.4 8.4 15.6 10.3 23.2 12.1
95% CI 11.6-13.1 10.6-12.2 12.2-14.3 10.9-13.8 7.1-9.8 12.4-18.8 7.3-13.8 16.0-31.0 11.6-12.5
AS rate (W) 12.1 11.1 12.9 12.0 8.2 15.1 10.1 22.9 11.8
95% CI 11.3-12.9 10.3-11.9 11.8-13.9 10.6-13.4 6.9-9.5 12.0-18.2 7.1-13.5 15.9-30.2 11.4-12.2
Note: Rates are expressed per 100,000 women and age standardised to the Australian 1991 population (A) and the
World Standard Population (W).
Source: National Cancer Statistics Clearing House (AIHW).
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Source: National Cancer Statistics Clearing House (AIHW).
Table 17b: Age-standardised incidence rates for cervical cancer by histological type for
women, all ages, Australia, 1987-1998
Table 16a: Number of new cases of cervical cancer by histological type for women aged 20-69
years, Australia, 1987-1998
Histological type 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998
Squamous 657 642 669 620 633 600 587 617 532 519 445 472
Adenocarcinoma 125 150 102 144 137 133 135 189 134 142 124 134
Adeno-squamous 41 40 48 50 44 51 47 40 34 39 33 30
Other 70 67 75 78 80 57 76 71 64 53 42 58
Total 893 899 894 892 894 841 845 917 764 753 644 694
   Micro-invasive 89 86 88 140 156 149 134 169 176 145 115 116
Source: National Cancer Statistics Clearing House (AIHW).
Table 16b: Age-standardised incidence rates for cervical cancer by histological type for women
aged 20-69 years, Australia, 1987-1998
Histological type 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998
Squamous 13.3 12.6 12.8 11.7 11.6 10.9 10.5 10.9 9.2 8.8 7.5 7.8
Adenocarcinoma 2.5 3.0 2.0 2.7 2.4 2.4 2.4 3.3 2.3 2.4 2.1 2.2
Adeno-squamous 0.8 0.8 0.9 0.9 0.8 0.9 0.8 0.7 0.6 0.7 0.5 0.5
Other 1.4 1.3 1.4 1.5 1.4 1.0 1.4 1.2 1.1 0.9 0.7 1.0
   Micro-invasive 1.8 1.7 1.7 2.6 2.9 2.7 2.4 3.0 3.1 2.5 2.0 1.9
Notes: Rates are expressed per 100,000 women and age standardised to the Australian 1991 population
Source: National Cancer Statistics Clearing House (AIHW).
Table 17a: Number of new cases of cervical cancer by histological type for women, all ages,
Australia, 1987-1998
Histological type 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998
Squamous 800 759 788 746 776 738 692 766 656 652 538 591
Adenocarcinoma 139 169 122 166 164 147 156 210 161 158 149 154
Adeno-squamous 47 45 53 56 51 56 56 50 39 46 39 35
Other 100 92 93 94 105 77 114 98 96 70 68 88
Total 1,086 1,065 1,056 1,062 1,096 1,018 1,018 1,124 952 926 794 868
    Micro-invasive 90 87 90 145 166 153 140 180 188 152 121 122
Histological type 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998
Squamous 12.5 11.9 12.3 11.8 12.1 11.2 10.5 11.3 9.8 9.5 7.3 7.9
Adenocarcinoma 2.4 2.7 1.9 2.7 2.5 2.3 2.4 3.2 2.4 2.3 2.1 2.2
Adeno-squamous 0.8 0.7 0.9 0.9 0.8 0.9 0.8 0.7 0.6 0.7 0.6 0.5
Other 1.4 1.2 1.4 1.4 1.5 1.1 1.6 1.4 1.4 1.1 0.9 1.2
   Micro-invasive 1.6 1.5 1.5 2.4 2.7 2.5 2.2 2.8 2.9 2.3 1.8 1.8
Notes: Rates are expressed per 100,000 women and age standardised to the Australian 1991 population.
Source: National Cancer Statistics Clearing House (AIHW).
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Indicator 8: Incidence by location
Table 18: Number of new cases of cervical cancer by age and location, 1995-1997 and
1996-1998
Metropolitan Rural Remote
Age group 1995-1997 1996-1998 1995-1997 1996-1998 1995-1997 1996-1998
0-4 0 0 0 0 0 0
5-9 0 0 0 0 0 0
10-14 0 0 0 0 0 0
15-19 3 2 1 1 0 0
20-24 18 23 11 14 0 0
25-29 99 97 35 30 2 4
30-34 171 157 75 68 11 6
35-39 259 234 78 92 17 15
40-44 254 242 76 69 7 12
45-49 223 220 51 65 6 7
50-54 157 160 49 54 4 5
55-59 127 114 46 48 7 7
60-64 129 121 49 44 4 4
65-69 140 138 45 35 11 7
70-74 137 124 35 36 4 3
75-79 103 102 39 35 3 2
80-84 73 79 27 29 1 2
85+ 69 62 14 18 2 2
All ages 1,961 1,874 631 638 79 77
Ages 20-69
years 1,576 1,505 515 519 69 67
Note: The numbers are presented as 3-year rolling blocks of data.
Source: National Cancer Statistics Clearing House (AIHW).
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Table 19: Age-specific and age-standardised incidence rates for cervical cancer by age and
location, 1995-1997 and 1996-1998
Metropolitan Rural Remote
Age group 1995-1997 1996-1998 1995-1997 1996-1998 1995-1997 1996-1998
0-4 0.0 0.0 0.0 0.0 0.0 0.0
5-9 0.0 0.0 0.0 0.0 0.0 0.0
10-14 0.0 0.0 0.0 0.0 0.0 0.0
15-19 0.2 0.1 0.2 0.2 0.0 0.0
20-24 1.1 1.5 2.7 3.6 0.0 0.0
25-29 6.2 5.9 7.7 6.7 3.1 5.8
30-34 10.9 10.0 14.4 13.4 15.7 9.1
35-39 16.6 14.8 14.0 16.1 25.6 22.9
40-44 17.3 16.2 14.7 13.0 12.3 21.6
45-49 16.1 15.7 10.9 13.6 13.5 14.0
50-54 14.5 13.8 12.7 13.1 10.6 12.2
55-59 14.8 12.9 13.6 13.9 26.3 24.5
60-64 17.3 16.0 15.7 14.2 16.8 17.5
65-69 18.8 18.8 15.1 11.6 63.6 39.6
70-74 19.7 17.7 12.9 13.2 33.5 23.7
75-79 19.6 18.5 19.6 16.9 32.4 21.0
80-84 19.2 20.6 19.0 20.1 15.3 28.3
85+ 22.6 19.3 12.5 15.2 32.0 31.0
All ages
AS rate (A) 9.3 8.7 8.5 8.4 12.2 11.1
95% CI 8.9-9.7 8.3-9.1 7.8-9.1 7.8-9.1 9.4-15.1 8.6-13.7
AS rate (W) 7.6 7.2 7.0 6.9 9.6 9.0
95% CI 7.3-8.0 6.8-7.5 6.4-7.5 6.4-7.5 7.6-12.0 6.8-11.0
Ages 20-69 years
AS rate (A) 12.5 11.7 11.6 11.5 16.1 14.9
95% CI 11.9-13.0 11.1-12.2 10.6-12.5 10.6-12.6 12.2-20.1 11.1-18.4
AS rate (W) 12.2 11.4 11.3 11.3 15.1 14.3
95% CI 11.6-12.7 10.9-12.0 10.3-12.2 10.3-12.3 11.5-18.9 10.7-17.7
Notes
1. The numbers are presented as 3-year rolling blocks of data.
2. Rates are expressed per 100,000 women and age standardised to the Australian 1991 population (A) and the
World Standard Population (W).
Source: National Cancer Statistics Clearing House (AIHW).
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Indicator 7: Mortality
Table 20: Number of deaths from cervical cancer by age, Australia, 1989-1999
Age group 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999
0-4 0 0 0 0 0 0 0 0 0 0 0
5-9 0 0 0 0 0 0 0 0 0 0 0
10-14 0 0 0 0 0 0 0 0 0 0 0
15-19 1 1 0 0 0 0 1 0 0 0 0
20-24 1 1 3 0 0 0 0 1 0 3 1
25-29 3 10 5 5 2 6 3 1 2 6 2
30-34 21 14 13 15 11 11 7 13 8 5 6
35-39 18 31 25 19 25 11 16 23 18 20 7
40-44 24 37 19 28 33 29 21 20 16 19 18
45-49 32 37 30 27 23 36 33 31 28 16 25
50-54 28 17 21 13 30 38 27 13 22 23 15
55-59 20 25 26 23 20 27 35 22 25 16 14
60-64 34 35 34 32 26 24 31 21 22 29 15
65-69 55 44 36 26 31 38 38 30 31 21 21
70-74 49 26 38 46 39 34 44 42 37 28 30
75-79 30 33 31 33 29 31 31 39 35 26 26
80-84 24 8 22 36 24 27 28 22 26 26 19
85+ 22 25 33 23 24 24 20 24 30 30 21
All ages 362 344 336 326 317 336 335 302 300 269 220
Ages 20-69
years 236 251 212 188 201 220 211 175 172 158 124
Source: AIHW Mortality Database.
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Table 21: Age-specific and age-standardised mortality rates for cervical cancer by age,
Australia, 1989-1999
1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999
0-4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5-9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
10-14 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15-19 0.1 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0
20-24 0.2 0.1 0.4 0.0 0.0 0.0 0.0 0.1 0.0 0.5 0.2
25-29 0.4 1.4 0.7 0.7 0.3 0.9 0.4 0.1 0.3 0.8 0.3
30-34 3.1 2.0 1.8 2.1 1.5 1.5 1.0 1.8 1.1 0.7 0.8
35-39 2.8 4.7 3.8 2.8 3.6 1.6 2.2 3.2 2.4 2.7 0.9
40-44 4.0 6.0 3.0 4.4 5.1 4.4 3.1 2.9 2.3 2.7 2.5
45-49 7.0 7.7 6.0 5.0 4.0 6.0 5.4 4.8 4.4 2.5 3.8
50-54 7.2 4.2 5.1 3.1 6.9 8.4 5.7 2.6 4.1 4.0 2.5
55-59 5.5 7.0 7.2 6.3 5.3 7.0 8.8 5.4 6.0 3.7 3.1
60-64 9.2 9.4 9.2 8.8 7.2 6.7 8.7 5.9 6.1 7.8 4.0
65-69 16.0 12.6 10.2 7.4 8.7 10.7 10.7 8.5 8.8 6.0 6.1
70-74 18.4 9.6 13.5 15.7 12.8 10.7 13.6 12.8 11.3 8.5 9.1
75-79 14.0 15.0 13.7 14.4 12.6 13.6 13.3 16.0 13.7 9.7 9.2
80-84 17.9 5.7 15.1 23.8 15.2 16.2 16.2 12.5 14.5 14.4 10.6
85+ 21.3 23.7 30.0 19.9 19.7 18.8 14.9 16.9 20.1 19.2 12.7
All ages
AS rate (A) 5.3 5.0 4.6 4.4 4.2 4.4 4.3 3.7 3.6 3.2 2.5
AS rate (W) 4.8 4.6 4.2 3.8 3.8 4.0 3.9 3.2 3.1 2.8 2.2
Ages 20-69 years
AS rate (A) 4.5 4.7 3.9 3.4 3.6 3.8 3.6 3.0 2.8 2.6 2.0
AS rate (W) 4.6 4.7 4.0 3.4 3.6 4.0 3.7 3.0 2.9 2.7 2.0
Notes
1. Rates for all ages are based on data for women aged 20 years and over.
2. Rates are expressed per 100,000 women and age standardised to the Australian 1991 Population (A) and the
World Standard Population (W).
Source: AIHW Mortality Database.
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Table 22: Number of deaths from cervical cancer by age, States and Territories, for the 4-year
period 1992-1995
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0-4 0 0 0 0 0 0 0 0 0
5-9 0 0 0 0 0 0 0 0 0
10-14 0 0 0 0 0 0 0 0 0
15-19 1 0 0 0 0 0 0 0 1
20-24 0 0 0 0 0 0 0 0 0
25-29 4 3 7 1 0 0 1 0 16
30-34 16 12 5 7 3 1 0 0 44
35-39 26 14 18 7 4 1 0 1 71
40-44 44 25 20 12 5 4 0 1 111
45-49 41 27 18 16 6 4 3 4 119
50-54 44 19 21 10 4 5 2 3 108
55-59 38 22 14 12 7 8 2 2 105
60-64 39 25 16 12 10 7 2 2 113
65-69 49 40 21 10 6 6 0 1 133
70-74 65 38 23 15 10 8 1 3 163
75-75 45 31 24 7 10 3 2 2 124
80-84 40 27 21 8 14 2 2 1 115
85+ 30 32 8 11 5 4 1 0 91
All ages 482 315 216 128 84 53 16 20 1,314
Ages 20-69
years 301 187 140 87 45 36 10 14 820
Notes
1. Numbers were averaged over four years to smooth annual variations that may occur in the smaller States and
Territories.
2. Deaths derived from place of usual residence and not place of death.
Source: AIHW Mortality Database.
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Table 23: Age-specific and age-standardised mortality rates for cervical cancer by age, by
States and Territories, for the 4-year period 1992-1995
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0-4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5-9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
10-14 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15-19 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
20-24 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
25-29 0.4 0.4 1.5 0.4 0.0 0.0 2.0 0.0 0.6
30-34 1.6 1.6 1.0 2.5 1.3 1.3 0.0 0.0 1.5
35-39 2.8 2.0 3.7 2.5 1.8 1.4 0.0 3.5 2.6
40-44 5.0 3.8 4.3 4.6 2.3 5.8 0.0 4.0 4.2
45-49 5.2 4.6 4.3 7.3 3.1 6.6 6.9 20.5 5.1
50-54 7.2 4.2 6.7 6.0 2.7 10.5 6.9 23.7 6.0
55-59 7.1 5.6 5.4 8.7 5.3 19.3 9.5 25.0 6.9
60-64 7.6 6.7 6.7 9.7 7.8 17.8 11.9 35.5 7.9
65-69 9.6 10.8 9.0 8.6 4.5 15.5 0.0 25.5 9.4
70-74 14.6 11.8 11.4 15.2 8.4 23.0 7.8 112.9 13.2
75-75 13.5 13.0 15.8 9.5 11.3 11.2 23.6 119.5 13.5
80-84 17.2 15.8 20.2 14.8 22.3 10.9 36.4 121.4 17.7
85+ 17.1 23.5 10.0 26.3 10.3 30.1 26.0 0.0 18.2
All ages
AS rate (A) 4.5 3.9 4.2 4.8 3.0 6.5 4.2 18.1 4.3
95% CI 4.1-4.9 3.5-4.4 3.6-4.9 3.9-5.6 2.4-3.7 4.8-8.4 2.3-6.4 9.4-28.0 4.1-4.6
AS rate (W) 5.8 5.0 5.0 5.5 4.1 8.1 3.8 8.8 5.3
95% CI 5.3-6.3 4.5-5.6 4.3-5.7 4.6-6.5 3.2-5.0 5.9-10.2 1.9-5.8 4.9-12.8 5.0-5.6
Ages 20-69 years
AS rate (A) 3.9 3.2 3.6 4.2 2.3 5.9 2.9 10.4 3.6
95% CI 3.4-4.3 2.8-3.7 3.0-4.2 3.3-5.1 1.6-3.0 4.1-8.0 1.2-4.8 4.6-16.7 3.4-3.9
AS rate (W) 4.0 3.3 3.6 4.1 2.4 6.2 2.6 6.9 3.7
95% CI 3.5-4.4 2.8-3.7 3.0-4.2 3.3-5.0 1.7-3.1 4.1-8.2 1.0-4.4 3.4-10.8 3.4-3.9
Notes
1. The age-standardised rates were averaged over four years to smooth annual variations that may occur in the
smaller States and Territories.
2. Deaths derived from place of usual residence and not place of death.
3. Rates for all ages are based on data for women aged 20 years and over.
4. Rates are expressed per 100,000 women and age standardised to the Australian 1991 Population (A) and the
World Standard Population (W).
Source: AIHW Mortality Database.
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Table 24: Number of deaths from cervical cancer by age, States and Territories, for the 4-year
period 1996-1999
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0-4 0 0 0 0 0 0 0 0 0
5-9 0 0 0 0 0 0 0 0 0
10-14 0 0 0 0 0 0 0 0 0
15-19 0 0 0 0 0 0 0 0 0
20-24 1 2 2 0 0 0 0 0 5
25-29 0 3 4 2 1 0 1 0 11
30-34 7 8 7 8 1 1 0 0 32
35-39 27 13 11 7 4 3 0 3 68
40-44 30 16 14 6 0 1 4 2 73
45-49 40 19 14 10 8 3 3 3 100
50-54 30 11 16 6 3 3 3 1 73
55-59 26 13 17 9 7 3 1 1 77
60-64 27 19 18 6 6 10 0 1 87
65-69 39 20 15 14 7 3 4 1 103
70-74 47 38 23 12 12 2 1 2 137
75-79 44 29 29 6 10 6 0 2 126
80-84 31 34 13 8 5 2 0 0 93
85+ 42 19 14 18 8 3 2 0 106
All ages 391 244 197 112 72 40 19 16 1,091
Ages 20-69
years 227 124 118 68 37 27 16 12 629
Notes
1. Numbers were averaged over four years to smooth annual variations that may occur in the smaller States and
Territories.
2. Deaths derived from place of usual residence and not place of death.
Source: AIHW Mortality Database.
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Table 25: Age-specific and age-standardised mortality rates for cervical cancer by age, by
States and Territories, for the 4-year period 1996-1999
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0-4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5-9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
10-14 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15-19 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
20-24 0.1 0.3 0.4 0.0 0.0 0.0 0.0 0.0 0.2
25-29 0.0 0.4 0.7 0.7 0.5 0.0 1.9 0.0 0.4
30-34 0.7 1.1 1.4 2.9 0.5 1.5 0.0 0.0 1.1
35-39 2.7 1.8 2.0 2.4 1.7 4.0 0.0 9.6 2.3
40-44 3.2 2.3 2.8 2.1 0.0 1.4 8.0 7.3 2.6
45-49 4.6 2.9 2.9 3.9 3.8 4.5 6.1 13.0 3.9
50-54 4.0 2.0 3.9 2.9 1.6 5.3 7.8 5.9 3.3
55-59 4.4 3.0 5.5 5.7 4.9 6.6 3.9 9.7 4.5
60-64 5.3 5.0 7.1 4.5 4.7 25.2 0.0 15.0 5.9
65-69 7.8 5.5 6.3 11.6 5.6 7.9 25.3 22.0 7.3
70-74 10.0 11.1 10.5 11.2 9.7 5.7 6.9 63.3 10.4
75-75 11.7 10.7 16.5 7.1 9.9 20.5 0.0 98.6 12.0
80-84 12.2 18.4 10.9 13.6 7.3 9.8 0.0 0.0 13.0
85+ 19.6 11.7 14.0 34.4 13.4 18.3 38.9 0.0 17.3
All ages
AS rate (A) 3.3 2.8 3.4 3.7 2.4 4.7 4.1 10.6 3.2
95% CI 3.0-3.7 2.5-3.2 2.9-3.9 3.0-4.4 1.9-3.0 3.3-6.2 2.4-6.0 4.9-17.7 3.0-3.4
AS rate (W) 2.7 2.0 2.7 3.0 1.8 4.3 4.2 6.8 2.6
95% CI 2.4-3.1 1.7-2.4 2.2-3.3 2.3-3.8 1.2-2.4 2.7-6.0 2.2-6.6 2.7-11.6 2.4-2.8
Ages 20-69 years
AS rate (A) 2.9 2.3 2.9 3.2 2.1 4.2 3.8 8.7 2.8
95% CI 2.6-3.2 2.0-2.6 2.5-3.4 2.5-3.8 1.5-2.6 2.9-5.7 2.1-5.6 4.5-13.5 2.6-3.0
AS rate (W) 2.7 2.0 2.7 2.9 1.8 4.4 4.1 6.7 2.6
95% CI 2.3-3.1 1.7-2.4 2.3-3.2 2.2-3.6 1.2-2.4 2.7-6.0 2.2-6.3 3.0-11.0 2.4-2.8
Notes
1. The age-standardised rates were averaged over four years to smooth annual variations that may occur in the
smaller States and Territories.
2. Deaths derived from place of usual residence and not place of death.
3. Rates for all ages are based on data for women aged 20 years and over.
4. Rates are expressed per 100,000 women and age standardised to the Australian 1991 Population (A) and the
World Standard Population (W).
Source: AIHW Mortality Database.
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Table 26: Number of deaths from cervical cancer by age and location, 1996-1998 and
1997-1999
Metropolitan Rural Remote
Age group 1996-1998 1997-1999 1996-1998 1997-1999 1996-1998 1997-1999
0-4 0 0 0 0 0 0
5-9 0 0 0 0 0 0
10-14 0 0 0 0 0 0
15-19 0 0 0 0 0 0
20-24 3 3 1 1 0 0
25-29 6 6 3 3 0 1
30-34 19 13 6 5 1 1
35-39 39 29 19 14 3 2
40-44 35 38 17 11 3 4
45-49 48 51 22 15 5 3
50-54 44 45 13 14 1 1
55-59 42 35 20 17 1 3
60-64 47 47 22 18 3 1
65-69 55 50 22 19 5 4
70-74 73 66 30 25 4 4
75-75 69 60 29 25 2 2
80-84 55 52 17 16 2 3
85+ 65 56 20 24 0 1
All ages 600 551 241 208 30 30
Ages 20-69 years 338 317 145 117 22 20
Notes
1. Deaths derived from place of usual residence and not place of death.
2. The number of deaths is presented as 3-year rolling blocks of data.
Source: AIHW Mortality Database.
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Table 27: Age-specific and age-standardised mortality rates for cervical cancer by age and
location, 1996-1998 and 1997-1999
Metropolitan Rural Remote
Age group 1996-1998 1997-1999 1996-1998 1997-1999 1996-1998 1997-1999
0-4 0.0 0.0 0.0 0.0 0.0 0.0
5-9 0.0 0.0 0.0 0.0 0.0 0.0
10-14 0.0 0.0 0.0 0.0 0.0 0.0
15-19 0.0 0.0 0.0 0.0 0.0 0.0
20-24 0.2 0.2 0.2 0.3 0.0 0.0
25-29 0.4 0.4 0.7 0.7 0.0 1.4
30-34 1.2 0.8 1.2 1.0 1.4 1.4
35-39 2.5 1.8 3.3 2.5 4.5 3.0
40-44 2.4 2.5 3.2 2.0 5.3 6.9
45-49 3.4 3.6 4.6 3.1 10.5 6.2
50-54 3.8 3.7 3.2 3.3 2.6 2.4
55-59 4.8 3.8 5.7 4.7 3.5 10.1
60-64 6.2 6.1 7.0 5.6 14.0 4.5
65-69 7.5 6.9 7.3 6.3 28.4 22.3
70-74 10.4 9.4 11.1 9.1 29.5 28.6
75-75 12.6 10.4 13.9 11.5 20.8 19.7
80-84 14.3 13.5 11.7 11.0 28.3 40.4
85+ 20.3 16.5 16.8 19.0 0.0 14.1
All ages
AS rate (A) 3.7 3.4 4.1 3.4 7.4 7.0
95% CI 3.4-4.0 3.1-3.7 3.6-4.6 2.9-3.8 4.7-10.2 4.5-9.8
AS rate (W) 3.3 3.0 3.7 3.0 6.5 6.0
95% CI 3.0-3.6 2.7-3.3 3.2-4.1 2.6-3.5 4.2-9.1 3.9-8.3
Ages 20-69 years
AS rate (A) 2.6 2.4 3.1 2.4 5.5 4.7
95% CI 2.4-2.9 2.2-2.7 2.5-3.6 2.0-2.9 3.3-7.9 2.8-7.0
AS rate (W) 2.6 2.4 3.0 2.4 5.3 4.5
95% CI 2.3-2.9 2.1-2.7 2.5-3.5 2.0-2.9 3.2-7.7 2.7-6.7
Notes
1. The age-standardised rates are presented as 3-year rolling blocks of data.
2. Deaths derived from place of usual residence and not place of death.
3. Rates for all ages are based on data for women aged 20 years and over.
4. Rates are expressed per 100,000 women and age standardised to the Australian 1991 Population (A) and the
World Standard Population (W).
Source: AIHW Mortality Database.
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Table 28: Number of deaths from cervical cancer by age, by Indigenous and non-Indigenous
status, WA, SA, NT, 1996-1998 and 1997-1999
Indigenous Non-Indigenous
Age group 1993-1995 1996-1998 1997-1999 1993-1995 1996-1998 1997-1999
0-4 0 0 0 0 0 0
5-9 0 0 0 0 0 0
10-14 0 0 0 0 0 0
15-19 0 0 0 0 0 0
20-24 0 0 0 0 0 0
25-29 0 0 1 0 3 3
30-34 0 1 1 6 6 6
35-39 0 2 2 10 11 6
40-44 1 2 4 15 4 4
45-49 5 3 2 14 10 13
50-54 3 0 0 13 7 8
55-59 1 1 1 16 12 10
60-64 2 2 1 19 7 10
65-69 2 2 1 13 15 12
70-74 1 2 2 17 17 16
75+ 1 1 3 46 44 44
All ages 16 16 18 169 136 132
Ages 20-69 years 14 13 13 106 75 72
Notes
1. Deaths derived from place of usual residence and not place of death.
2. The number of deaths is presented as 3-year rolling blocks of data for the latter two time periods.
3. Only Western Australia, South Australia and the Northern Territory have Indigenous death registration data
considered to be of a publishable standard.
Source: AIHW Mortality Database.
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Table 29: Age-specific and age-standardised mortality rates for cervical cancer by age, by
Indigenous and non-Indigenous status, WA, SA, NT, 1993-1995, 1996-1998 and 1997-1999
Indigenous Non-Indigenous
Age group 1993-1995 1996-1998 1997-1999 1993-1995 1996-1998 1997-1999
0-4 0.0 0.0 0.0 0.0 0.0 0.0
5-9 0.0 0.0 0.0 0.0 0.0 0.0
10-14 0.0 0.0 0.0 0.0 0.0 0.0
15-19 0.0 0.0 0.0 0.0 0.0 0.0
20-24 0.0 0.0 0.0 0.0 0.0 0.0
25-29 0.0 0.0 5.3 0.0 0.8 0.8
30-34 0.0 6.2 6.0 1.5 1.6 1.6
35-39 0.0 15.1 14.6 2.6 2.7 1.5
40-44 11.1 18.7 35.9 4.1 1.0 1.0
45-49 71.1 38.9 24.9 4.3 2.8 3.6
50-54 61.1 0.0 0.0 5.3 2.4 2.6
55-59 23.4 23.9 23.4 7.7 5.3 4.3
60-64 62.2 56.7 28.1 10.0 3.6 5.1
65-69 88.3 80.3 39.2 7.0 8.1 6.5
70-74 73.4 131.1 127.6 10.2 9.8 9.2
75+ 49.0 48.7 149.3 16.4 14.0 13.6
All ages
AS rate (A) 27.7 25.6 29.0 4.6 3.4 3.2
95% CI 13.8-44.1 13.0-39.8 13.9-44.3 3.9-5.3 2.8-3.9 2.7-3.7
AS rate (W) 27.5 23.3 23.5 4.1 2.9 2.8
95% CI 14.1-42.5 12.5-36.1 12.1-35.0 3.5-4.8 2.4-3.4 2.3-3.4
Ages 20-69 years
AS rate (A) 24.1 19.0 15.8 3.4 2.3 2.2
95% CI 11.9-37.6 9.0-31.2 6.8-24.6 2.8-4.1 1.8-2.9 1.7-2.7
AS rate (W) 25.1 18.5 15.3 3.5 2.3 2.2
95% CI 12.5-39.3 8.6-30.9 6.6-24.3 2.8-4.1 1.8-2.8 1.7-2.7
Notes
1. The age-standardised rates are presented as 3-year rolling blocks of data for the latter two time periods.
2. Deaths derived from place of usual residence and not place of death.
3. Rates for all ages are based on data for women aged 20 years and over.
4. Rates are expressed per 100,000 women and age standardised to the Australian 1991 Population (A) and the
World Standard Population (W).
5. Only Western Australia, South Australia and the Northern Territory have Indigenous death registration data
considered to be of a publishable standard.
Source: AIHW Mortality Database.
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Appendix A: Cervical cancer: symptoms, detection
and treatment
Cervical cancer affects the cells lining the cervix, which is the lower part of the womb or uterus
where it joins the inner end of the vagina. Like other cancers, cervical cancer is a disease where
normal cells change, begin to multiply out of control, and form a growth or tumour. The cancer
may arise from the squamous cells at the transformation zone where the squamous cells on the
outside of the cervix join the columnar cells in the lining of the cervical canal (squamous cell
carcinoma) or from the cells in the cervical canal (adenocarcinoma). Over two-thirds of cervical
cancers are squamous cell carcinomas, which are most easily detected on the Pap smear, while
about 20% are adenocarcinomas. If not detected early, the tumour can invade local tissue and
spread or metastasise to other parts of the body. The main symptoms of cervical cancer are
unusual bleeding from the vagina and, very rarely, an unusual vaginal discharge. However, these
symptoms are quite common and may not be due to cancer.
A cervical cancer may take 10 or more years to develop, but before this the cells may show
pre-cancerous changes. These early changes can be detected by a Pap smear, which is described
in more detail below. Cervical cancer can be prevented with early treatment of these
abnormalities. The most recent classification of these pre-cancerous lesions has two levels of
severity, low-grade epithelial abnormalities (LGEA) and high-grade epithelial abnormalities
(HGEA). An earlier classification described various grades of cervical intra-epithelial
neoplasia (CIN). Low-grade abnormalities include minor changes in squamous cells and CIN 1
while high-grade abnormalities include CIN 2, CIN 3, squamous carcinoma in situ,
adenocarcinoma in situ and invasive carcinoma (squamous or adenocarcinoma).
The Pap smear is the most common way to detect pre-cancerous changes, which rarely cause any
symptoms. The test involves a doctor inserting a speculum into the vagina and gently scraping
the surface of the cervix. This process collects cells that are transferred onto a slide or into a
special liquid, which is then sent to a pathology laboratory for assessment. Pap smears are
offered by general practitioners, gynaecologists, family planning clinics, women’s health centres,
hospital outpatient clinics and, in some circumstances, specially trained nurses.
If the Pap smear shows an abnormality, the woman may be advised to have a repeat Pap smear if
the abnormality is low-grade or she may be advised to have a colposcopy. With colposcopy, a
doctor is able to look directly at the cervix under magnification using an instrument called a
colposcope. Using a special stain the doctor can highlight any suspicious area, which may be
pre-cancerous or cancerous. The doctor will then take a tissue sample (a biopsy) of the
suspicious area for further examination by the pathologist.
Pre-cancerous changes can easily be treated to prevent the progression to cervical cancer. The
type of treatment depends on whether the change observed is low or high grade, the woman’s age
and general health, whether she wants to have children, and her preferences.
There is a range of treatments for pre-cancerous changes, including laser treatment, loop excision
(LLETZ), cryosurgery (cold coagulation), electrodiathermy or cone biopsy (either by laser or by
scalpel). In a small number of instances a hysterectomy may be necessary.
For invasive cancer, a cone biopsy or hysterectomy is generally performed. If the cancer cells are
only detected on the surface of the cervix, it may be treated by a cone biopsy. If it has invaded
deeper into the cervix a hysterectomy is generally performed. In advanced cases, a radical
hysterectomy is needed to remove the cervix and uterus along with a margin of tissue around the
cervix and lymph nodes from the pelvis. Radiotherapy is sometimes used as well as surgery, and
for more advanced cases it may be used on its own.
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Appendix B:  Data sources and limitations
All data used in this report are based on calendar years. Data are derived from multiple sources
and are summarised below.
Table B1: Cervical screening indicators data sources
Indicator Description Data source
1 Participation rate for cervical screening National Cervical Screening Program
2 Early rescreening National Cervical Screening Program
3 Low-grade abnormality detection National Cervical Screening Program
4 High-grade abnormality detection National Cervical Screening Program
5 Incidence of micro-invasive cervical cancer
National Cancer Statistics Clearing House
(ICD 180)
National Cancer Statistics Clearing
House
6, 8 Incidence of squamous, adenocarcinoma,
adeno-squamous and other cervical cancer
(ICD 180)
National Cancer Statistics Clearing
House
7, 9, 10 Mortality from cervical cancer (ICD9 180)
For 1999 data (ICD10 C539)
Population data
The Australian Bureau of Statistics estimated resident female population has been used to
calculate incidence and mortality rates. Participation rates were calculated using the average of
the 1998 and 1999 estimated resident female population (see Appendix D for tables). There may
be some variation in published participation rates because national rates use estimated resident
population data in the denominator whereas local data analysis may use census counts. The
denominator population used to calculate cervical screening participation rates has been adjusted
by the estimated proportion of women who have had a hysterectomy by age. These data were
derived from the 1995 National Health Survey, and are tabled in Appendix D.
The age-standardised rates in this publication are calculated using the total estimated 1991
mid-year Australian resident population. Where appropriate, rates are also standardised to the
World Standard Population for international comparison. Both the Australian and World
Standard Populations are in Appendix D.
Cervical screening
Indicators 1-4 do not include data from Queensland because the cervical screening register in
Queensland was not operational at the time of data processing. The incidence and mortality data
used in Indicators 5-9 include Queensland.
Due to the difficulties of Indigenous identification, mortality data used in Indicator 10 are based
on deaths in Western Australia, South Australia and the Northern Territory only.
Other data limitations
• Hysterectomy fractions are calculated using national data derived from the National Health
Survey using aggregate data that does not necessarily reflect variation at the State or Territory
level.
• Participation rates will be underestimates to the extent that a small percentage of women
choose to opt-off local registers.
AIHW Mortality Database
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• The participation numbers for States and Territories other than WA and ACT, and the
Australian totals, may be overestimated because of double counting of some women in
registers. This may be the result of difficulty in identifying State or Territory of residence for
women in border areas and the inclusion in registers of women resident overseas.
• Participation rates published by State and Territory programs may differ from those in this
publication because of variation in denominators used.
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Appendix C:  Methods
This section describes the methods employed to calculate the estimates presented in the tables in
the body of this publication.
Crude rates
A crude rate is defined as the number of events over a specified period of time (e.g. a year)
divided by the total population. For example, a crude cancer incidence rate is similarly defined as
the number of new cases of cancer in a specified period of time divided by the population at risk.
Crude mortality rates and cancer incidence rates are expressed in this report as rates per 100,000
population. Crude participation rate is expressed as a percentage.
Age-specific rates
Age-specific rates are calculated by dividing the number of cases occurring in each specified age
group by the corresponding population in the same age group expressed as a percentage or a rate
per 1,000 or 100,000 population. This rate may be calculated for particular age and sex
groupings, e.g.
Age-specific
cervical cancer
incidence rates in
females aged 50-54
= X 100,000
= 76
New cases 1997 aged 50-54 years
1997 female population aged 50-54 years
536,230
X 100,000
= 14.2 per 100,000
Age-standardised rates (AS rate)
Rates are adjusted for age to facilitate comparisons between populations that have different age
structures, e.g. between youthful and ageing communities. There are two different methods
commonly used to adjust for age. In this publication we use direct standardisation in which
age-specific rates are multiplied against a constant population (the Australian 1991 Standard
Population unless otherwise specified). This effectively removes the influence of age structure on
the summary rate that is described as the age-standardised rate. The method may be used for the
calculation of participation, incidence and mortality rates. The method used for this calculation
comprises three steps.
Step 1: Calculate the age-specific rate (as shown above) for each age group.
Step 2: Calculate the expected number of cases in each 5-year age group by multiplying the
age-specific rates by the corresponding standard population and dividing by 100,000,
giving you the expected number of cases.
Step 3: Sum the expected number of cases in each age group to give the age-standardised rate.
Divide this sum by the total of the standard population and multiply by 100,000.
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Confidence intervals
Population numbers for incidence, mortality and screening have a natural level of variability for a
single year above and below what might be expected in the mean over many years. The
percentage variability is small for large population numbers but high for small numbers such as
mortality in a young age group. One measure of the likely difference is the standard error, which
indicates the extent to which a population number might have varied by chance in only one year
of data.
In the 95% confidence interval there are about nineteen chances in twenty that the difference will
be less than two standard errors.
The 95% confidence intervals in this report were calculated using the software package
Palisade@risk (http://www.palisade.com). These calculations were based on 1,000 simulations
using a binomial or Poisson distribution with the observed data to calculate the distribution
parameters.
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Appendix D:  Population data
Table D1: Australian Standard Population(1) and World Standard Population(2)
Age group World Standard Population (W) Australian 1991 Standard Population (A)
0-4 12,000 1,271,703
5-9 10,000 1,272,208
10-14 9,000 1,241,619
15-19 9,000 1,364,074
20-24 8,000 1,396,764
25-29 8,000 1,399,663
30-34 6,000 1,425,735
35-39 6,000 1,328,387
40-44 6,000 1,294,271
45-49 6,000 1,029,145
50-54 5,000 846,934
55-59 4,000 725,950
60-64 4,000 736,868
65-69 3,000 671,390
70-74 2,000 510,755
75-79 1,000 384,495
80-84 500 229,828
85+ 500 154,247
Total 100,000 17,284,036
Sources: 1. Australian Bureau of Statistics (1993); 2. Doll and Smith (1982).
Table D2: Hysterectomy fractions for women aged 18-80+ years, Australia, 1995
Age group % of women who have not had a hysterectomy
18-19 98.4
20-24 99.8
25-29 99.3
30-34 98.0
35-39 91.9
40-44 85.2
45-49 79.1
50-54 68.5
55-59 68.5
60-64 67.8
65-69 68.8
70-74 66.8
75-79 66.8
80+ 61.5
Total 84.3
Source: Australian Bureau of Statistics 1995.
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Table D3: Estimated resident female populations, by States and Territories, June 1998
Age
group NSW Vic Qld WA SA Tas ACT NT Australia
0-4 211,964 151,230 118,238 61,590 46,451 15,566 10,462 8,599 624,234
5-9 216,598 156,623 122,769 64,891 48,262 16,882 10,785 8,227 645,215
10-14 212,926 154,468 121,554 66,277 49,492 17,415 10,863 7,568 640,736
15-19 211,691 156,110 122,923 64,859 48,307 16,804 11,724 6,801 639,297
20-24 219,602 167,409 126,100 67,118 49,190 15,037 13,223 7,940 665,691
25-29 246,280 186,409 136,225 71,206 53,605 16,466 13,292 9,531 733,145
30-34 237,843 180,162 128,250 69,463 53,750 16,601 12,265 8,436 706,925
35-39 253,091 185,703 137,485 73,996 58,855 18,924 12,781 7,923 748,913
40-44 235,756 174,788 128,226 70,927 55,553 17,901 12,324 7,007 702,629
45-49 216,581 161,284 119,578 64,508 53,063 16,475 12,174 5,783 649,539
50-54 192,250 142,523 105,601 53,595 47,242 14,574 9,998 4,445 570,287
55-59 147,772 108,537 78,235 40,092 35,929 11,424 6,505 2,646 431,183
60-64 129,092 95,392 63,813 33,488 31,816 9,980 4,771 1,754 370,123
65-69 123,457 90,160 59,496 30,121 30,876 9,500 3,946 1,136 348,707
70-74 117,664 86,057 55,247 26,908 30,802 8,806 3,614 806 329,909
75-79 95,504 69,353 44,979 21,587 25,717 7,403 2,866 513 267,923
80-84 64,393 46,276 30,230 14,665 17,197 5,165 1,752 316 180,000
85+ 54,706 41,424 25,580 13,305 15,255 4,173 1,310 249 156,006
Total 3,187,170 2,353,908 1,724,529 908,596 751,362 239,096 154,655 89,680 9,410,462
Source: AIHW Population Database based on estimated resident population data compiled by ABS.
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Table D4: Estimated resident female populations, by States and Territories, June 1999
Age
group NSW Vic Qld WA SA Tas ACT NT Australia
0-4 210,825 149,345 117,830 61,742 46,022 15,373 10,369 8,481 620,101
5-9 217,147 157,607 124,506 64,778 48,311 16,591 10,727 8,378 648,219
10-14 213,517 155,122 122,073 66,783 48,963 17,091 10,794 7,465 641,992
15-19 214,180 157,811 125,527 65,940 49,288 16,951 11,568 7,015 648,380
20-24 218,587 167,569 125,120 67,885 48,428 14,750 13,024 7,837 663,257
25-29 248,403 186,122 136,228 71,363 52,440 16,005 13,157 9,524 733,363
30-34 236,656 181,447 128,549 69,303 53,023 16,123 12,164 8,579 706,004
35-39 254,383 187,302 139,312 74,660 58,441 18,625 12,635 8,055 753,568
40-44 238,135 176,533 130,717 71,804 56,080 17,940 12,380 6,971 710,706
45-49 220,757 164,621 122,514 66,279 53,683 16,750 12,104 6,019 662,831
50-54 198,358 147,675 110,532 56,265 48,969 15,085 10,507 4,711 592,163
55-59 154,145 113,036 82,604 41,983 37,196 11,878 6,866 2,900 450,656
60-64 131,505 96,830 66,557 34,641 32,448 10,136 4,947 1,767 378,852
65-69 121,817 90,079 59,234 30,379 30,570 9,450 4,002 1,178 346,720
70-74 117,014 85,765 55,803 27,180 30,571 8,771 3,655 818 329,585
75-79 100,326 73,381 46,982 22,832 26,932 7,774 3,118 538 281,885
80-84 63,969 45,675 30,432 14,329 17,045 5,104 1,796 316 178,671
85+ 57,752 43,539 27,214 14,152 16,105 4,430 1,431 276 164,903
Total 3,217,476 2,379,459 1,751,734 922,298 754,515 238,827 155,244 90,828 9,511,856
Source: AIHW Population Database based on estimated resident population data compiled by ABS.
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Glossary
Ablative therapy: the destruction of cells on the surface of the cervix using laser therapy,
chemicals or diathermy.
ABS: Australian Bureau of Statistics.
ACT: Australian Capital Territory-a land-locked Territory of Australia situated within the State
of New South Wales on the eastern seaboard with a population of 309,794 (1997). Its capital city
is Canberra, which is also Australia’s capital city.
Adjuvant: enhancing or administered to enhance the effectiveness of a treatment or substance.
AHMAC: Australian Health Ministers’ Advisory Council.
AIHW: Australian Institute of Health and Welfare.
ASGC: Australian Standard Geographical Classification: the classification designed by the ABS
to define the geography of Australia.
AS rate: age-standardised rate
Basement membrane: the delicate, noncellular layer on which an epithelium is seated. The
epithelium forms the surface portion of the skin and lines hollow organs and all passages of the
respiratory, digestive and genito-urinary systems.
Benign: not malignant.
Cancer (malignant neoplasm): a term used to describe one of several diseases which result
when the process of cell division, by which tissues normally grow and renew themselves,
becomes uncontrolled and leads to the development of malignant cells. These cancer cells
multiply in an uncoordinated way, independently of normal growth control mechanisms, to form
a tumour. This tumour may expand locally by invasion or systemically by metastasis via the
lymphatic or vascular systems. If left untreated most malignant tumours will eventually result in
death.
Cancer death: a death where the underlying cause is indicated as cancer. Persons with cancer
dying of other causes are not counted in the death statistics in this publication.
CIN (cervical intraepithelial neoplasia): Squamous cell carcinoma of the cervix is mostly
preceded, over a period of years, by a spectrum of asymptomatic abnormalities known as
cervical intraepithelial neoplasia (CIN) graded as CIN 1 (mild dysplasia), CIN 2 (moderate
dysplasia) and CIN 3 (severe dysplasia and carcinoma in situ). CIN usually occurs at least a
decade before cervical cancer. If CIN remains untreated, some women will develop cervical
cancer. It is difficult to anticipate which cases of CIN will regress or progress although a number
of international studies have shown that 1% of CIN 1, 5% of CIN 2 and more than 12% of CIN 3
would progress to invasive cervical cancer (Jelfs 1995).
Colposcopy: a microscopic examination of the lower genital tract with a magnifying instrument
called a colposcope. This method of conservative evaluation allows the clinician to more
accurately assess the cytologic abnormality by focussing on the areas of greatest cellular
abnormality and by sampling them with a punch biopsy to attain diagnosis.
DHAC: Commonwealth Department of Health and Aged Care (since October 1998)
(Department of Health and Ageing since November 2001).
DHFS: Commonwealth Department of Health and Family Services (to October 1998).
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DHSH: Commonwealth Department of Human Services and Health (1994-1996).
Epidemiology: the quantitative study of the distribution and determinants of health-related states
and events in populations, and the application of this study to the control of health problems.
HGA: high-grade abnormalities - as defined for this report include CIN 1/2, CIN 2, CIN 3 or
adenocarcinoma in situ.
Hysterectomy: refers to the surgical procedure whereby all or part of the uterus is removed.
Hysterectomy fractions: the proportion of women who have had their uterus removed by
hysterectomy.
HPV: Human papilloma virus.
ICD-9: International Classification of Disease-a coding system used to identify the primary site
of the malignancy. This classification is in its ninth revision.
Incidence: see new cancer case
Intraepithelial: refers to that area within the layer of cell tissues forming the epidermis of a
body cavity. These cells comprise contiguous cells having minimum intercellular substance.
Invasive cancer: a tumour whose cells have a tendency to invade healthy or normal tissues.
LGA: low-grade abnormalities include atypia, warty atypia (human papilloma virus (HPV)
effect), possible CIN, equivocal CIN, CIN 1 or endocervical dysplasia not otherwise specified
(NOS).
Lymph node: masses of lymphatic tissue, often bean-shaped, that produce lymphocytes and
through which lymph filters. These are located throughout the body.
Metastasis: the process by which a disease is transferred from one part of the body to another,
for example, via the lymphatic system or the bloodstream.
Mortality: see cancer death
New cancer case: a person who has a new cancer diagnosed for the first time. One person may
have more than one cancer and therefore may be counted twice in incidence statistics if it is
decided that the two cancers are not of the same origin. This decision is based on a series of
principles set out in more detail in a publication by Jensen et al. (1991).
NOS: Not otherwise specified.
NSW: New South Wales-a State of Australia on the eastern seaboard which has the largest
capital city in Australia, Sydney, and a population of 6,274,370 (1997).
NT: Northern Territory-a Territory in the north of Australia with a population of 187,132 (1997)
and Darwin as its capital city.
Pap smear: a test prepared for the study of exfoliated cells from the cervix (refer to Appendix A:
Cervical cancer: symptoms, detection and treatment).
Post-partum: following childbirth.
Qld: Queensland-a State in the north-east of Australia with a population of 3,401,232 (1997) and
Brisbane as its capital city.
Radiation therapy: the treatment of disease with any type of radiation, most commonly with
ionising radiation, such as x-rays, beta rays and gamma rays.
RRMA: Rural, Remote and Metropolitan Areas Classification.
SA: South Australia-a State in the southern part of Australia with a population of 1,479,806
(1997) and Adelaide as its capital city.
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Screening: the performance of tests on apparently well people in order to detect a medical
condition at an earlier stage than would otherwise be the case.
Sensitivity: the proportion of individuals with the disease whom the screening test labels
positive.
Stroma: the supporting framework of an organ.
Tas: Tasmania-an island State in the south-east of Australia with a population of 473,501 (1997)
and Hobart as its capital city.
Vic: Victoria-a State in the south-east of Australia with a population of 4,605,148 (1997) and
Melbourne as its capital city.
WA: Western Australia-the largest State in Australia, located in the west with a population of
1,798,129 (1997) and Perth as its capital city.
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